Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | PPARG | P37231 | 5/20 | 0.44 |
| ▸ | PPARA | Q07869 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | PPARD | Q03181 | 3/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 7/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.40 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.40 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29101 | 1.00 | MEN1 (0.45) | MEN1KMT2ANPC1PPARGPPARA | |
| SCHEMBL502 | 0.82 | TSHR (0.52) | KMT2ANPC1ALDH1A1RAB9AL3MBTL1 | |
| SCHEMBL8881644 | 0.82 | TSHR (0.52) | KMT2ANPC1ALDH1A1RAB9AL3MBTL1 | |
| SCHEMBL6510845 | 0.81 | PTGS2 (0.46) | NPC1PPARAPPARDMAPTRAB9A | |
| SCHEMBL1456261 | 0.81 | PTGS2 (0.46) | NPC1PPARAPPARDMAPTRAB9A | |
| SCHEMBL7617607 | 0.80 | TSHR (0.50) | KMT2ANPC1PPARGALDH1A1RAB9A | |
| SCHEMBL131471 | 0.79 | IDO1 (0.55) | NPC1RAB9AHTTTSHRLMNA | |
| SCHEMBL27597789 | 0.78 | TSHR (0.48) | KMT2ANPC1ALDH1A1RAB9AL3MBTL1 | |
| SCHEMBL2920835 | 0.77 | ALDH1A1 (0.40) | MEN1KMT2ANPC1ALDH1A1TRPA1 | |
| Cyanide SCHEMBL27392144 | 0.76 | TSHR (0.46) | MEN1KMT2ANPC1ALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 719 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1514542-B1 | Medicinal composition comprising Tacrine or Donepezil for improving brain function. | TOYAMA CHEMICAL CO LTD (JP) | 2012-02-22 | — | — | EP | claimed |
| EP-0695750-B1 | Naphthyridinium derivative, method for its production; antibody against said derivative and the use of said antibody | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 2000-03-01 | — | — | EP | claimed |
| EP-0362941-B1 | 4-Methyl and 4-ethyl substituted pyrrolidin-2-ones | MERCK SHARP & DOHME (GB) | 1995-12-20 | — | — | EP | claimed |
| EP-0389437-B1 | Luciferin derivatives | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 1995-05-24 | — | — | EP | claimed |
| EP-0220923-B1 | Dipeptides and process | GRACE W R & CO (US) | 1994-04-27 | — | — | EP | claimed |
| US-5128069-A | Luciferin derivatives | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 1992-07-07 | — | — | US | claimed |
| US-5120746-A | Inhibit gastric acid secretion | TOYAMA CHEMICAL CO., LTD. (JP) | 1992-06-09 | — | — | US | claimed |
| US-4810817-A | ARTIFICIAL SWEETENERS | W. R. GRACE & CO. (US) | 1989-03-07 | — | — | US | claimed |
| US-4767863-A | Isoxazoline intermediates | BRISTOL-MYERS COMPANY (US) | 1988-08-30 | — | — | US | claimed |
| US-4710583-A | ENZYMATIC COUPLING OF PHENYLSERINE WITH ASPARTIC ACID; HYDROGENATION | W. R. GRACE & CO. (US) | 1987-12-01 | — | — | US | claimed |
| US-4643849-A | ANTIULCER, ANTISECRETORY AGENTS | TOYAMA CHEMICAL CO., LTD. (JP) | 1987-02-17 | — | — | US | claimed |
| US-4267340-A | BACTERICIDES; SYNTHESIS OF PENICILLINS AND CEPHALOSPORINS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-05-12 | — | — | US | claimed |
| EP-0011283-A1 | New lactyl tetrapeptide, processes for preparation thereof and pharmaceutical compositions containing it | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-05-28 | — | — | EP | claimed |
| US-4176009-A | HYDROLYZING OLIGOPEPTIDES IN A AQUEOUS SOLUTION TO RELEASE PEPTIDE FRAGMENTS, USING COLORIMETRIC ANALYSIS AFTER SOLVENT EXTRACTION | AJINOMOTO CO., INC. (JP) | 1979-11-27 | — | — | US | claimed |
| US-4138394-A | Peptide derivatives and a method of measuring collagenase activity | AJINOMOTO CO., INC. (JP) | 1979-02-06 | — | — | US | claimed |
| US-4086136-A | Process for producing a peptide using a serine or thiol proteinase | (ZAIDANHOJIN) SAGAMI CHEMICAL RESEARCH CENTER (JA) | 1978-04-25 | — | — | US | claimed |
| US-4009159-A | PENICILLINS | FUJISAWA PHARMACEUTICAL CO., LTD. (JA) | 1977-02-22 | — | — | US | claimed |
| US-3993646-A | Process for the ring expansion of penicillins to cephalosporin compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JA) | 1976-11-23 | — | — | US | claimed |
| US-3978063-A | 1,2,3,4-Tetrahydroisoquinoline derivatives and the preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JA) | 1976-08-31 | — | — | US | claimed |
| US-12016843-B2 | Compositions and methods for the treatment of amyotrophic lateral sclerosis, parkinson's disease, parkinson's disease with dementia, dementia with lewy bodies, and multiple system atrophy | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-06-25 | — | — | US | disclosed |
| CN-111527067-B | Process for the preparation of 1- [5- (2-fluorophenyl) -1- (pyridin-3-ylsulfonyl) -1H-pyrrol-3-yl ] -N-methylmethylamine monofumarate | 日本化学药品株式会社 | 2024-06-25 | — | — | CN | disclosed |
| CN-111954539-B | Mitochondrial targeting peptides | 隐形生物治疗公司 | 2024-06-21 | — | — | CN | disclosed |
| EP-4119560-B1 | APOPTOSIS-INDUCING AGENTS | FOCHON PHARMACEUTICALS LTD (CN) | 2024-06-05 | — | — | EP | disclosed |
| WO-2024092154-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASE | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| EP-3768661-B1 | DEUTERATED COMPOUNDS AS ROCK INHIBITORS | FOCHON PHARMACEUTICALS LTD (CN) | 2024-05-01 | — | — | EP | disclosed |
| US-11964026-B2 | Layer-by-layer nanoparticles for cytokine therapy in cancer treatment | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2024-04-23 | — | — | US | disclosed |
| US-20240092832-A1 | DEUTERATED TETRAPEPTIDES THAT TARGET MITOCHONDRIA | STEALTH BIOTHERAPEUTICS INC. | 2024-03-21 | — | — | US | disclosed |
| EP-3565815-B1 | COMPOUNDS AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS | FOCHON PHARMACEUTICALS LTD (CN) | 2024-03-13 | — | — | EP | disclosed |
| CN-117624286-A | Mitochondrial targeting peptides | 隐形生物治疗公司 | 2024-03-01 | — | — | CN | disclosed |
| US-20240059734-A1 | MITOCHONDRIA-TARGETING PEPTIDES | STEALTH BIOTHERAPEUTICS INC. | 2024-02-22 | — | — | US | disclosed |
| US-11897864-B2 | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2024-02-13 | — | — | US | disclosed |
| US-20240043404-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2024-02-08 | — | — | US | disclosed |
| US-20230406856-A1 | SUBSTITUTED PYRROLO [2, 3-b] PYRIDINE AND PYRAZOLO [3, 4-b] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2023-12-21 | — | — | US | disclosed |
| US-20230405080-A1 | METHODS AND COMPOSITIONS FOR TREATING, PREVENTING, INHIBITING, AMELIORATING OR DELAYING THE ONSET OF OPHTHALMIC CONDITIONS | STEALTH BIOTHERAPEUTICS INC. (US) | 2023-12-21 | — | — | US | disclosed |
| WO-2023224989-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HUNTINGTON'S DISEASE AND HTT PROTEINOPATHIES | STEALTH BIOTHERAPEUTICS INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| CN-110678550-B | Long-acting adrenomedullin derivatives | 国立大学法人宫崎大学 | 2023-11-14 | — | — | CN | disclosed |
| EP-2435432-B3 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE IRELAND UNLIMITED CO (BM) | 2023-10-25 | — | — | EP | disclosed |
| US-11795196-B2 | Mitochondria-targeting peptides | STEALTH BIOTHERAPEUTICS INC. (US) | 2023-10-24 | — | — | US | disclosed |
| EP-3765462-B1 | SUBSTITUTED (2-AZABICYCLO [3.1.0] HEXAN-2-YL) PYRAZOLO [1, 5-A] PYRIMIDINE AND IMIDAZO [1, 2-B] PYRIDAZINE COMPOUNDS AS TRK KINASES INHIBITORS | FOCHON BIOSCIENCES LTD (CN) | 2023-10-18 | — | — | EP | disclosed |
| US-11786519-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230279052-A1 | PRODRUGS OF MITOCHONDRIA-TARGETING OLIGOPEPTIDES | STEALTH BIOTHERAPEUTICS INC. | 2023-09-07 | — | — | US | disclosed |
| US-11730826-B2 | Amphiphilic nanoparticles for delivery of CRISPR based therapy | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-08-22 | — | — | US | disclosed |
| WO-2023153507-A1 | PHARMACEUTICAL COMPOSITION FOR PERITONEAL DISORDER | 国立大学法人宮崎大学 | 2023-08-17 | — | — | WO | disclosed |
| US-20230256047-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MUSCULAR DYSTROPHY | STEALTH BIOTHERAPEUTICS INC. (US) | 2023-08-17 | — | — | US | disclosed |
| EP-4218785-A2 | MITOCHONDRIA-TARGETING PEPTIDES | Stealth BioTherapeutics Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20230227499-A1 | PRODRUGS OF MITOCHONDRIA-TARGETING OLIGOPEPTIDES | STEALTH BIOTHERAPEUTICS INC. | 2023-07-20 | — | — | US | disclosed |
| WO-2023133321-A1 | SMALL MOLECULE PEPTIDOMIMETIC FOR THE TREATMENT OF TAUOPATHIES | STEALTH BIOTHERAPEUTICS INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| EP-3452484-B1 | CERTAIN PROTEIN KINASE INHIBITORS | FOCHON PHARMACEUTICALS LTD (CN) | 2023-07-05 | — | — | EP | disclosed |
| US-20230201367-A1 | LAYER-BY-LAYER NANOPARTICLES FOR CYTOKINE THERAPY IN CANCER TREATMENT | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2023-06-29 | — | — | US | disclosed |
| WO-2023107611-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF MUSCULAR DYSTROPHY | STEALTH BIOTHERAPEUTICS INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| US-20230174556-A1 | COMPOUNDS AS PROTEIN KINASE INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2023-06-08 | — | — | US | disclosed |
| US-20230174607-A1 | Novel Adrenomedullin Analog, Method for Producing the Same, and Pharmaceutical Use Thereof | UNIVERSITY OF MIYAZAKI (JP) | 2023-06-08 | — | — | US | disclosed |
| US-20230159527-A1 | COMPOUNDS AS BCL-2 INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230146515-A1 | MITOCHONDRIA-TARGETING PEPTIDES | STEALTH BIOTHERAPEUTICS INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230145305-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| US-20230143532-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230142095-A1 | Long-Acting Adrenomedullin Derivative | UNIVERSITY OF MIYAZAKI (JP) | 2023-05-11 | — | — | US | disclosed |
| US-20230135215-A1 | COMPOUNDS AS CDK2/4/6 INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2023-05-04 | — | — | US | disclosed |
| CN-116034159-A | Novel adrenomedullin analogue, preparation method and medical application thereof | 国立大学法人宫崎大学 | 2023-04-28 | — | — | CN | disclosed |
| WO-2023069255-A1 | METHODS AND COMPOSITIONS COMPRISING PEPTIDOMIMITICS FOR TREATING, PREVENTING, INHIBITING, AMELIORATING OR DELAYING THE ONSET OF OPHTHALMIC CONDITIONS | STEALTH BIOTHERAPEUTICS INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023069549-A1 | METHODS AND COMPOSITIONS COMPRISING PEPTIDOMIMITICS FOR TREATING, PREVENTING, INHIBITING, AMELIORATING OR DELAYING THE ONSET OF OPHTHALMIC CONDITIONS | STEALTH BIOTHERAPEUTICS INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| EP-4168425-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MUSCULAR DYSTROPHY | Stealth BioTherapeutics Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| EP-4168424-A1 | PRODRUGS OF MITOCHODRIA-TARGETING OLIGOPEPTIDES | Stealth BioTherapeutics Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| EP-4168423-A1 | PRODRUGS OF MITOCHODRIA-TARGETING OLIGOPEPTIDES | Stealth BioTherapeutics Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| US-20230120030-A1 | Long-Acting Adrenomedullin Derivatives | UNIVERSITY OF MIYAZAKI (JP) | 2023-04-20 | — | — | US | disclosed |
| CN-115916208-A | Methods and compositions for treating muscular dystrophy | 康德生物医疗有限公司 | 2023-04-04 | — | — | CN | disclosed |
| US-11613743-B2 | Process for the production and purification of the collagenase enzyme from Vibrio alginolyticus | FIDIA FARMACEUTICI S.P.A. (IT) | 2023-03-28 | — | — | US | disclosed |
| EP-3723783-B1 | MITOCHONDRIA-TARGETING PEPTIDES | STEALTH BIOTHERAPEUTICS INC (US) | 2023-02-15 | — | — | EP | disclosed |
| US-11578112-B2 | Long-acting adrenomedullin derivative conjugated with Fc region of immunoglobulin | UNIVERSITY OF MIYAZAKI (JP) | 2023-02-14 | — | — | US | disclosed |
| EP-4130264-A1 | NOVEL ADRENOMEDULLIN ANALOG, METHOD FOR PRODUCING THE SAME, AND PHARMACEUTICAL USE THEREOF | University of Miyazaki (JP) | 2023-02-08 | — | — | EP | disclosed |
| EP-4119560-A1 | APOPTOSIS-INDUCING AGENTS | Shanghai Fochon Pharmaceutical Co., Ltd. (CN) | 2023-01-18 | — | — | EP | disclosed |
| US-20220402913-A1 | APOPTOSIS-INDUCING AGENTS | FOCHON PHARMACEUTICALS, LTD. (CN) | 2022-12-22 | — | — | US | disclosed |
| US-11485707-B2 | Deuterated compounds as rock inhibitors | FOCHON PHARMACEUTICALS, LTD. (CN) | 2022-11-01 | — | — | US | disclosed |
| CN-114805540-A | Long-acting adrenomedullin derivative | 国立大学法人宫崎大学 | 2022-07-29 | — | — | CN | disclosed |
| EP-3288931-B2 | CERTAIN PROTEIN KINASE INHIBITOR | CHONGQING FOCHON PHARMACEUTICAL CO LTD (CN) | 2022-07-20 | — | — | EP | disclosed |
| EP-4001280-A1 | METHOD FOR PRODUCING PHENOL DERIVATIVE | Nippon Chemiphar Co., Ltd. (JP) | 2022-05-25 | — | — | EP | disclosed |
| EP-3986401-A1 | THE PEPTIDOMIMETIC COMPOUND (R)-2-AMINO-N-((S)-L-(((S)-5-AMINO-L-(3-BENZYL-1,2,4-OXADIAZOL-5-YL)PENTYL)AMINO)-3-(4-HYDROXY-2,6-DIMETHYLPHENYL)-I-OXOPROPAN-2-YL)-5-GUANIDINOPENTANAMIDE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | Stealth BioTherapeutics Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| CN-108026182-B | Long-acting adrenomedullin derivative | 国立大学法人宫崎大学 | 2022-04-26 | — | — | CN | disclosed |
| EP-3984982-A1 | METHOD FOR PRODUCING MORPHINAN DERIVATIVE | Nippon Chemiphar Co., Ltd. (JP) | 2022-04-20 | — | — | EP | disclosed |
| US-11273149-B2 | Compositions and methods for the treatment of amyotrophic lateral sclerosis, Parkinson's disease, Parkinson's disease with dementia, dementia with Lewy bodies, and multiple system atrophy | STEALTH BIOTHERAPEUTICS INC. (US) | 2022-03-15 | — | — | US | disclosed |
| CN-114127069-A | Process for producing phenol derivative | 日本化学药品株式会社 | 2022-03-01 | — | — | CN | disclosed |
| CN-114127076-A | Process for producing morphinan derivative | 日本化学药品株式会社 | 2022-03-01 | — | — | CN | disclosed |
| US-20220041588-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2022-02-10 | — | — | US | disclosed |
| EP-3397627-B1 | INDOLIZINE DERIVATIVES, COMPOSITION AND METHODS OF USE | SHANGHAI FOCHON PHARMACEUTICAL CO LTD (CN) | 2022-01-26 | — | — | EP | disclosed |
| WO-2021262708-A1 | PRODRUGS OF MITOCHODRIA-TARGETING OLIGOPEPTIDES | STEALTH BIOTHERAPEUTICS CORP. (KY) | 2021-12-30 | — | — | WO | disclosed |
| WO-2021262710-A1 | PRODRUGS OF MITOCHODRIA-TARGETING OLIGOPEPTIDES | STEALTH BIOTHERAPEUTICS CORP. (KY) | 2021-12-30 | — | — | WO | disclosed |
| WO-2021257673-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MUSCULAR DYSTROPHY | STEALTH BIOTHERAPEUTICS INC. (US) | 2021-12-23 | — | — | WO | disclosed |
| CN-106164088-B | Long-acting adrenomedullin derivative | 国立大学法人宫崎大学 | 2021-11-23 | — | — | CN | disclosed |
| US-20210346369-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2021-11-11 | — | — | US | disclosed |
| EP-3898653-A1 | ANALOGS THAT TARGET MITOCHONDRIAL DISEASES | Stealth Biotherapeutics Corp (MC) | 2021-10-27 | — | — | EP | disclosed |
| EP-3898652-A1 | MITOCHONDRIA-TARGETING PEPTIDES | Stealth Biotherapeutics Corp (MC) | 2021-10-27 | — | — | EP | disclosed |
| CN-113544138-A | Mitochondrial targeting peptides | 隐形生物治疗公司 | 2021-10-22 | — | — | CN | disclosed |
| CN-113383005-A | Analogs targeting mitochondrial disorders | 隐形生物治疗公司 | 2021-09-10 | — | — | CN | disclosed |
| US-20210253634-A1 | PROCESS FOR THE LIQUID PHASE SYNTHESIS OF H-INP-(D)BAL-(D)TRP-PHE-APC-NH2, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | ALLERGAN GI CORP (US) | 2021-08-19 | — | — | US | disclosed |
| US-11091478-B2 | Apoptosis-inducing agents | FOCHON PHARMACEUTICAL CO., LTD. (CN) | 2021-08-17 | — | — | US | disclosed |
| US-20210228565-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2021-07-29 | — | — | US | disclosed |
| US-20210221789-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2021-07-22 | — | — | US | disclosed |
| US-11053239-B2 | Compounds as BLC-2-selective apoptosis-inducing agents | FOCHON PHARMACEUTICALS, LTD. (CN) | 2021-07-06 | — | — | US | disclosed |
| WO-2021132637-A1 | METHOD FOR PRODUCING CYCLIC SECONDARY AMINE | 日本ケミファ株式会社 | 2021-07-01 | — | — | WO | disclosed |
| US-11040089-B2 | Pharmaceutical compositions containing hyaluronic acid and collagenase for the topical treatment of wounds, burns and ulcers | FIDIA FARMACEUTICI S.P.A (IT) | 2021-06-22 | — | — | US | disclosed |
| WO-2021117754-A1 | AGENT FOR REPAIRING OR SUPPRESSING DNA DAMAGE | 国立研究開発法人国立循環器病研究センター | 2021-06-17 | — | — | WO | disclosed |
| WO-2021112220-A1 | THERAPEUTIC AGENT FOR NEURODEGENERATIVE DISEASE WITH ABNORMAL PROTEIN ACCUMULATION | 国立大学法人 宮崎大学 | 2021-06-10 | — | — | WO | disclosed |
| CN-112876552-A | Long-acting adrenomedullin derivative | 国立大学法人宫崎大学 | 2021-06-01 | — | — | CN | disclosed |
| US-20210115103-A1 | LONG-ACTING ADRENOMEDULLIN DERIVATIVE | UNIVERSITY OF MIYAZAKI (JP) | 2021-04-22 | — | — | US | disclosed |
| US-20210106679-A1 | Silaffin Silica Particle Adjuvant | Universität Wien (AT) | 2021-04-15 | — | — | US | disclosed |
| US-10961273-B2 | N-carboxyanhydride-based-scale synthesis of elamipretide | STEALTH BIOTHERAPEUTICS CORP. (MC) | 2021-03-30 | — | — | US | disclosed |
| US-20210070711-A1 | DEUTERATED COMPOUNDS AS ROCK INHIBITORS | FOCHON PHARMACEUTICALS, LTD. (CN) | 2021-03-11 | — | — | US | disclosed |
| WO-2021016462-A1 | THE PEPTIDOMIMETIC COMPOUND (R)-2-AMINO-N-((S)-L-(((S)-5-AMINO-L-(3-BENZYL-1,2,4-OXADIAZOL-5-YL)PENTYL)AMINO)-3-(4-HYDROXY-2,6-DIMETHYLPHENYL)-I-OXOPROPAN-2-YL)-5-GUANIDINOPENTANAMIDE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | STEALTH BIOTHERAPEUTICS CORP (MC) | 2021-01-28 | — | — | WO | disclosed |
| WO-2021015108-A1 | METHOD FOR PRODUCING MORPHINAN DERIVATIVE | 日本ケミファ株式会社 | 2021-01-28 | — | — | WO | disclosed |
| WO-2021015109-A1 | METHOD FOR PRODUCING PHENOL DERIVATIVE | 日本ケミファ株式会社 | 2021-01-28 | — | — | WO | disclosed |
| US-20210024528-A1 | SUBSTITUTED (2-AZABICYCLO[3.1.0]HEXAN-2-YL)PYRAZOLO[1,5-a]PYRIMIDINE AND IMIDAZO[1,2-b]PYRIDAZINE COMPOUNDS AS TRK KINASES INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2021-01-28 | — | — | US | disclosed |
| US-20210023062-A1 | Compositions and Methods for the Treatment of Amyotrophic Lateral Sclerosis, Parkinson's Disease, Parkinson's Disease with Dementia, Dementia with Lewy Bodies, and Multiple System Atrophy | STEALTH BIOTHERAPEUTICS INC. | 2021-01-28 | — | — | US | disclosed |
| US-10894038-B2 | Indolizine derivatives, composition and methods of use | SHANGHAI FOCHON PHARMACEUTICAL CO. LTD. (CN) | 2021-01-19 | — | — | US | disclosed |
| US-20210008219-A1 | LONG-ACTING ADRENOMEDULLIN DERIVATIVE | UNIVERSITY OF MIYAZAKI (JP) | 2021-01-14 | — | — | US | disclosed |
| US-10842879-B2 | Long-acting adrenomedullin derivative | UNIVERSITY OF MIYAZAKI (JP) | 2020-11-24 | — | — | US | disclosed |
| US-20200361987-A1 | DEUTERATED TETRAPEPTIDES THAT TARGET MITOCHONDRIA | STEALTH BIOTHERAPEUTICS INC. | 2020-11-19 | — | — | US | disclosed |
| CN-111954539-A | Mitochondrial targeting peptides | 隐形生物治疗公司 | 2020-11-17 | — | — | CN | disclosed |
| US-10835535-B2 | Certain protein kinase inhibitors | SHANGHAI FOCHON PHARMACEUTICAL CO., LTD. (CN) | 2020-11-17 | — | — | US | disclosed |
| US-20200354707-A1 | PROCESS FOR THE PRODUCTION AND PURIFICATION OF THE COLLAGENASE ENZYME FROM VIBRIO ALGINOLYTICUS | FIDIA FARMACEUTICI S.P.A. (IT) | 2020-11-12 | — | — | US | disclosed |
| US-20200345717-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2020-11-05 | — | — | US | disclosed |
| EP-3723783-A1 | MITOCHONDRIA-TARGETING PEPTIDES | Stealth Biotherapeutics Corp (MC) | 2020-10-21 | — | — | EP | disclosed |
| US-10800785-B2 | Substituted pyrrolo[2,3-d]pyridazin-4-ones and pyrazolo[3,4-d]pyridazin-4-ones as protein kinase inhibitors | SHANGHAI FOCHON PHARMACEUTICAL CO., LTD. (CN) | 2020-10-13 | — | — | US | disclosed |
| US-10774319-B2 | Process for the production and purification of the collagenase enzyme from vibrio alginolyticus | FIDIA FARMACEUTICI S.P.A. (IT) | 2020-09-15 | — | — | US | disclosed |
| US-20200277291-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2020-09-03 | — | — | US | disclosed |
| US-10751423-B2 | Nanoparticle conjugates of highly potent toxins and intraperitoneal administration of nanoparticles for treating or imaging cancer | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2020-08-25 | — | — | US | disclosed |
| US-20200253954-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2020-08-13 | — | — | US | disclosed |
| CN-111527067-A | Process for producing 1- [ 5- (2-fluorophenyl) -1- (pyridin-3-ylsulfonyl) -1H-pyrrol-3-yl ] -N-methylmethanemethanemetic acid salt | 日本化学药品株式会社 | 2020-08-11 | — | — | CN | disclosed |
| US-20200231566-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2020-07-23 | — | — | US | disclosed |
| US-20200222413-A1 | METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS | ABBVIE INC. | 2020-07-16 | — | — | US | disclosed |
| WO-2020131282-A1 | MITOCHONDRIA-TARGETING PEPTIDES | STEALTH BIOTHERAPEUTICS CORP. (MC) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020131283-A1 | ANALOGS THAT TARGET MITOCHONDRIAL DISEASES | STEALTH BIOTHERAPEUTICS CORP. (MC) | 2020-06-25 | — | — | WO | disclosed |
| EP-3666758-A1 | PROCESS FOR THE PREPARATION OF A SULFONAMIDE DERIVATIVE | AbbVie Inc. (US) | 2020-06-17 | — | — | EP | disclosed |
| US-20200172572-A1 | PROCESS FOR THE LIQUID PHASE SYNTHESIS OF H-INP-(D)BAL-(D)TRP-PHE-APC-NH2, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | ALLERGAN GI CORP (US) | 2020-06-04 | — | — | US | disclosed |
| EP-3656771-A1 | PROCESS FOR THE PREPARATION OF A SYNTHETIC INTERMEDIATE FOR APOPTOSIS-INDUCING AGENTS | AbbVie Ireland Unlimited Company (IE) | 2020-05-27 | — | — | EP | disclosed |
| WO-2020085234-A1 | MORPHINAN DERIVATIVE | 日本ケミファ株式会社 | 2020-04-30 | — | — | WO | disclosed |
| US-20200113876-A1 | INDOLIZINE DERIVATIVES, COMPOSITION AND METHODS OF USE | FOCHON PHARMACEUTICALS, LTD. (CN) | 2020-04-16 | — | — | US | disclosed |
| US-20200115379-A1 | APOPTOSIS-INDUCING AGENTS | FOCHON PHARMACEUTICALS, LTD. (CN) | 2020-04-16 | — | — | US | disclosed |
| EP-3612216-A1 | SILAFFIN SILICA PARTICLE ADJUVANT | Universität Wien (AT) | 2020-02-26 | — | — | EP | disclosed |
| CN-110785182-A | Silavidin (SILAFFIN) silica particle adjuvants | 维也纳大学 | 2020-02-11 | — | — | CN | disclosed |
| EP-3604538-A1 | LONG-ACTING ADRENOMEDULLIN DERIVATIVE | University of Miyazaki (JP) | 2020-02-05 | — | — | EP | disclosed |
| CN-110678550-A | Long-acting adrenomedullin derivative | 国立大学法人宫崎大学 | 2020-01-10 | — | — | CN | disclosed |
| US-20190345156-A1 | COMPOUNDS AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS | SHANGHAI FOCHON PHARMACEUTICAL CO., LTD. (CN) | 2019-11-14 | — | — | US | disclosed |
| EP-3288931-B1 | CERTAIN PROTEIN KINASE INHIBITOR | CHONGQING FOCHON PHARMACEUTICAL CO LTD (CN) | 2019-11-06 | — | — | EP | disclosed |
| US-10450316-B2 | Certain protein kinase inhibitor | Chongqing Fochon Pharmaceutical Co., Ltd. (CN) | 2019-10-22 | — | — | US | disclosed |
| US-20190315737-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2019-10-17 | — | — | US | disclosed |
| US-20190209566-A1 | CERTAIN PROTEIN KINASE INHIBITORS | FOCHON PHARMACEUTICALS, LTD. (CN) | 2019-07-11 | — | — | US | disclosed |
| US-20190202861-A1 | N-CARBOXYANHYDRIDE-BASED-SCALE SYNTHESIS OF ELAMIPRETIDE | STEALTH BIOTHERAPEUTICS INC. | 2019-07-04 | — | — | US | disclosed |
| EP-3500286-A1 | N-CARBOXYANHYDRIDE-BASED-SCALE SYNTHESIS OF ELAMIPRETIDE | Stealth BioTherapeutics Corp (MC) | 2019-06-26 | — | — | EP | disclosed |
| WO-2019118878-A1 | MITOCHONDRIA-TARGETING PEPTIDES | STEALTH BIOTHERAPEUTICS CORP. (MC) | 2019-06-20 | — | — | WO | disclosed |
| US-20190161489-A1 | SUBSTITUTED PYRROLO [2, 3-D] PYRIDAZIN-4-ONES AND PYRAZOLO [3, 4-D] PYRIDAZIN-4-ONES AS PROTEIN KINASE INHIBITORS | SHANGHAI FOCHON PHARMACEUTICAL CO., LTD. (CN) | 2019-05-30 | — | — | US | disclosed |
| US-20190125895-A1 | LAYER-BY-LAYER NANOPARTICLES FOR CYTOKINE THERAPY IN CANCER TREATMENT | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2019-05-02 | — | — | US | disclosed |
| US-20190119247-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2019-04-25 | — | — | US | disclosed |
| US-20180369250-A1 | METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS | ABBVIE INC. | 2018-12-27 | — | — | US | disclosed |
| WO-2018193039-A1 | SILAFFIN SILICA PARTICLE ADJUVANT | Universität Wien (AT) | 2018-10-25 | — | — | WO | disclosed |
| US-20180291027-A1 | CERTAIN PROTEIN KINASE INHIBITOR | FOCHON BIOSCIENCES, LTD. (CN) | 2018-10-11 | — | — | US | disclosed |
| US-20180264123-A1 | LONG-ACTING ADRENOMEDULLIN DERIVATIVE | UNIVERSITY OF MIYAZAKI (JP) | 2018-09-20 | — | — | US | disclosed |
| EP-3028702-B1 | METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS | ABBVIE IRELAND UNLIMITED CO (IE) | 2018-09-12 | — | — | EP | disclosed |
| US-20180251426-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2018-09-06 | — | — | US | disclosed |
| EP-2768830-B1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2018-08-29 | — | — | EP | disclosed |
| US-20180221363-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2018-08-09 | — | — | US | disclosed |
| EP-3351561-A1 | LONG-ACTING ADRENOMEDULLIN DERIVATIVE | University of Miyazaki (JP) | 2018-07-25 | — | — | EP | disclosed |
| US-20180170991-A1 | LONG-ACTING ADRENOMEDULLIN DERIVATIVES | UNIVERSITY OF MIYAZAKI (JP) | 2018-06-21 | — | — | US | disclosed |
| US-20180140595-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2018-05-24 | — | — | US | disclosed |
| US-9963483-B2 | Process for producing self-assembling peptide derivatives | MENICON CO., LTD. (JP) | 2018-05-08 | — | — | US | disclosed |
| EP-3312178-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Inc. (US) | 2018-04-25 | — | — | EP | disclosed |
| EP-2882439-B1 | APOPTOSIS-INDUCING AGENTS | ABBVIE INC (US) | 2018-04-11 | — | — | EP | disclosed |
| US-20180078657-A1 | AMPHIPHILIC NANOPARTICLES FOR DELIVERY OF CRISPR BASED THERAPY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2018-03-22 | — | — | US | disclosed |
| WO-2018034901-A1 | N-CARBOXYANHYDRIDE-BASED-SCALE SYNTHESIS OF ELAMIPRETIDE | STEALTH BIOTHERAPEUTICS (US) | 2018-02-22 | — | — | WO | disclosed |
| US-9877958-B2 | Apoptosis-induced agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-9872861-B2 | Methods of treatment using selective Bcl-2 inhibitors | ABBVIE INC. (US) | 2018-01-23 | — | — | US | disclosed |
| EP-3091017-B1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2018-01-17 | — | — | EP | disclosed |
| US-20180008687-A1 | NANOPARTICLE CONJUGATES OF HIGHLY POTENT TOXINS AND INTRAPERITONEAL ADMINISTRATION OF NANOPARTICLES FOR TREATING OR IMAGING CANCER | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2018-01-11 | — | — | US | disclosed |
| EP-3266776-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Inc. (US) | 2018-01-10 | — | — | EP | disclosed |
| EP-3262058-A1 | A COMPOUND FOR PREPARING POLYPEPTIDES | Universität Wien (AT) | 2018-01-03 | — | — | EP | disclosed |
| US-20170362609-A1 | AMPHIPHILIC NANOPARTICLES FOR CODELIVERY OF WATER-INSOLUBLE SMALL MOLECULES AND RNAi | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2017-12-21 | — | — | US | disclosed |
| US-9844547-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2017-12-19 | — | — | US | disclosed |
| WO-2017192573-A1 | NANOPARTICLE CONJUGATES OF HIGHLY POTENT TOXINS AND INTRAPERITONEAL ADMINISTRATION OF NANOPARTICLES FOR TREATING OR IMAGING CANCER | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2017-11-09 | — | — | WO | disclosed |
| WO-2017192544-A1 | AMPHIPHILIC NANOPARTICLES FOR CODELIVERY OF WATER-INSOLUBLE SMALL MOLECULES AND RNAi | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2017-11-09 | — | — | WO | disclosed |
| US-20170314005-A1 | NEW PROCESS FOR THE PRODUCTION AND PURIFICATION OF THE COLLAGENASE ENZYME FROM VIBRIO ALGINOLYTICUS | FIDIA FARMACEUTICI S.P.A. (IT) | 2017-11-02 | — | — | US | disclosed |
| US-20170296531-A9 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2017-10-19 | — | — | US | disclosed |
| US-9738883-B2 | Process for the production and purification of the collagenase enzyme from vibrio alginolyticus | FIDIA FARMACEUTICALS S.P.A. (IT) | 2017-08-22 | — | — | US | disclosed |
| US-20170232000-A9 | METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS | ABBVIE INC. | 2017-08-17 | — | — | US | disclosed |
| US-20170218015-A1 | PROCESS FOR THE LIQUID PHASE SYNTHESIS OF H-INP-(D)BAL-(D)TRP-PHE-APC-NH2, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | ALLERGAN GI CORP. | 2017-08-03 | — | — | US | disclosed |
| US-20170209552-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING HYALURONIC ACID AND COLLAGENASE FOR THE TOPICAL TREATMENT OF WOUNDS, BURNS AND ULCERS | FIDIA FARMACEUTICI S.P.A. (IT) | 2017-07-27 | — | — | US | disclosed |
| US-20170158666-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2017-06-08 | — | — | US | disclosed |
| US-20170096424-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2017-04-06 | — | — | US | disclosed |
| US-9603910-B2 | Pharmaceutical compositions containing hyaluronic acid and collagenase for the topical treatment of wounds, burns and ulcers | FIDIA FARMACEUTICI S.P.A. (IT) | 2017-03-28 | — | — | US | disclosed |
| EP-2376197-B1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2017-02-15 | — | — | EP | disclosed |
| EP-3127914-A1 | LONG-ACTING ADRENOMEDULLIN DERIVATIVES | University of Miyazaki (JP) | 2017-02-08 | — | — | EP | disclosed |
| EP-3114132-A1 | PROCESS FOR THE LIQUID PHASE SYNTHESIS OF H-INP-(D)BAL-(D)TRP-PHE-APC-NH2, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | MOTUS THERAPEUTICS, INC. (US) | 2017-01-11 | — | — | EP | disclosed |
| EP-3112361-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Inc. (US) | 2017-01-04 | — | — | EP | disclosed |
| EP-3101019-A1 | SULFONAMIDE DERIVATIVES AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | AbbVie Inc. (US) | 2016-12-07 | — | — | EP | disclosed |
| US-9493431-B2 | Apoptosis-inducing agent for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2016-11-15 | — | — | US | disclosed |
| EP-3091017-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Inc. (US) | 2016-11-09 | — | — | EP | disclosed |
| US-20160304451-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2016-10-20 | — | — | US | disclosed |
| EP-2507229-B1 | SULFONAMIDE DERIVATIVES AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | ABBVIE INC (US) | 2016-10-05 | — | — | EP | disclosed |
| EP-2642999-B1 | METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS | ABBVIE BAHAMAS LTD (BS) | 2016-09-28 | — | — | EP | disclosed |
| WO-2016135071-A1 | A COMPOUND FOR PREPARING POLYPEPTIDES | Universität Wien (AT) | 2016-09-01 | — | — | WO | disclosed |
| US-20160235760-A1 | METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS | ABBVIE INC (US) | 2016-08-18 | — | — | US | disclosed |
| EP-2766361-B1 | 8-CARBAMOYL-2-(2,3-DISUBSTITUTED PYRID-6-YL)-1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES AS APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2016-08-10 | — | — | EP | disclosed |
| US-9403822-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2016-08-02 | — | — | US | disclosed |
| EP-3048098-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | AbbVie Bahamas Limited (BS) | 2016-07-27 | — | — | EP | disclosed |
| US-20160206611-A1 | APOPTOSIS-INDUCED AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2016-07-21 | — | — | US | disclosed |
| EP-2387559-B1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2016-06-29 | — | — | EP | disclosed |
| US-20160158218-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2016-06-09 | — | — | US | disclosed |
| EP-3028702-A1 | METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS | AbbVie Bahamas Limited (BS) | 2016-06-08 | — | — | EP | disclosed |
| EP-2376480-B1 | SULFONAMIDE DERIVATIVES AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | ABBVIE INC (US) | 2016-06-01 | — | — | EP | disclosed |
| US-9345702-B2 | Methods of treatment using selective Bcl-2 inhibitors | ABBVIE INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-9315488-B2 | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases | ABBVIE INC. (US) | 2016-04-19 | — | — | US | disclosed |
| EP-2839000-B1 | NEW PROCESS FOR THE PRODUCTION AND PURIFICATION OF THE COLLAGENASE ENZYME FROM VIBRIO ALGINOLYTICUS | FIDIA FARMACEUTICI (IT) | 2016-04-13 | — | — | EP | disclosed |
| US-9303025-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2016-04-05 | — | — | US | disclosed |
| EP-2575463-B1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2016-03-30 | — | — | EP | disclosed |
| EP-1685119-B1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBVIE BAHAMAS LTD (BS) | 2016-03-09 | — | — | EP | disclosed |
| US-9266877-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-20160009687-A1 | BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | ABBVIE INC (US) | 2016-01-14 | — | — | US | disclosed |
| US-20160002187-A1 | APOPTOSIS-INDUCING AGENT FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2016-01-07 | — | — | US | disclosed |
| US-9227963-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2016-01-05 | — | — | US | disclosed |
| EP-2957558-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Inc. (US) | 2015-12-23 | — | — | EP | disclosed |
| US-20150329541-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2015-11-19 | — | — | US | disclosed |
| EP-2944638-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Bahamas Limited (BS) | 2015-11-18 | — | — | EP | disclosed |
| US-9174982-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-9156856-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2015-10-13 | — | — | US | disclosed |
| WO-2015134567-A1 | PROCESS FOR THE LIQUID PHASE SYNTHESIS OF H-INP-(D)BAL-(D)TRP-PHE-APC-NH2, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | RHYTHM PHARMACEUTICALS, INC. (US) | 2015-09-11 | — | — | WO | disclosed |
| US-9125913-B2 | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases | ABBVIE INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-20150246914-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2015-09-03 | — | — | US | disclosed |
| EP-2576546-B1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE BAHAMAS LTD (BS) | 2015-07-22 | — | — | EP | disclosed |
| US-9072748-B2 | BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases | ABBVIE INC. (US) | 2015-07-07 | — | — | US | disclosed |
| US-9073855-B2 | BCL-2 selective apoptosis-inducing agents for the treatment of cancer and immune diseases | ABBVIE INC. (US) | 2015-07-07 | — | — | US | disclosed |
| US-20150183775-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES | 2015-07-02 | — | — | US | disclosed |
| US-20150175663-A1 | Process for Producing Self-Assembling Peptide Derivatives | MENICON CO., LTD. (JP) | 2015-06-25 | — | — | US | disclosed |
| EP-2435432-B1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE BAHAMAS LTD (BS) | 2015-06-24 | — | — | EP | disclosed |
| EP-2882439-A1 | APOPTOSIS-INDUCING AGENTS | AbbVie Inc. (US) | 2015-06-17 | — | — | EP | disclosed |
| EP-2697247-B1 | METHOD FOR THE RAPID CHEMOENZYMATIC GLYCOSYLATION OF CONJUGATES BETWEEN PEPTIDES AND HYDROPHILIC POLYMERS | Universität Wien (AT) | 2015-06-17 | — | — | EP | disclosed |
| US-9051315-B2 | Imidazopyridines as a novel scaffold for multi-targeted kinase inhibition | ABBVIE INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-9051349-B2 | Larazotide acetate compositions | ALBA THERAPEUTICS CORPORATION (US) | 2015-06-09 | — | — | US | disclosed |
| US-20150150870-A1 | METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS | ABBVIE INC. | 2015-06-04 | — | — | US | disclosed |
| US-20150152097-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2015-06-04 | — | — | US | disclosed |
| US-9045420-B2 | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases | ABBVIE INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-9045444-B2 | Apoptosis promoters | ABBVIE INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-9045475-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2015-06-02 | — | — | US | disclosed |
| EP-2873677-A1 | METHOD OF PRODUCING SELF-ASSEMBLING PEPTIDE DERIVATIVE | Menicon Co., Ltd. (JP) | 2015-05-20 | — | — | EP | disclosed |
| US-9034875-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2015-05-19 | — | — | US | disclosed |
| US-9029404-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-9006247-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-20150072978-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2015-03-12 | — | — | US | disclosed |
| EP-2511264-B1 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC (US) | 2015-03-11 | — | — | EP | disclosed |
| US-20150056179-A1 | NEW PROCESS FOR THE PRODUCTION AND PURIFICATION OF THE COLLAGENASE ENZYME FROM VIBRIO ALGINOLYTICUS | FIDIA FARMACEUTICI S.P.A. (IT) | 2015-02-26 | — | — | US | disclosed |
| EP-2839000-A1 | NEW PROCESS FOR THE PRODUCTION AND PURIFICATION OF THE COLLAGENASE ENZYME FROM VIBRIO ALGINOLYTICUS | Fidia Farmaceutici S.p.A. (IT) | 2015-02-25 | — | — | EP | disclosed |
| US-8952157-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-8940737-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-20140377249-A1 | NEW PHARMACEUTICAL COMPOSITIONS CONTAINING HYALURONIC ACID AND COLLAGENASE FOR THE TOPICAL TREATMENT OF WOUNDS, BURNS AND ULCERS | FIDIA FARMACEUTICI S.P.A. (IT) | 2014-12-25 | — | — | US | disclosed |
| US-8900576-B2 | Pharmaceutical compositions containing hyaluronic acid and collagenase for the topical treatment of wounds, burns and ulcers | FIDIA FARMACEUTICI S.P.A (IT) | 2014-12-02 | — | — | US | disclosed |
| US-8889675-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2014-11-18 | — | — | US | disclosed |
| US-8883784-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-8865863-B2 | MCR dendrimers | Leibniz-Institut fur Pflandzenbiochemie (DE) | 2014-10-21 | — | — | US | disclosed |
| EP-2769711-A1 | Methods and Compositions for Enhanced Delivery of Macromolecules | ESBATech, an Alcon Biomedical Research Unit LLC (CH) | 2014-08-27 | — | — | EP | disclosed |
| EP-2768830-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Inc. (US) | 2014-08-27 | — | — | EP | disclosed |
| EP-2346877-B1 | PROCESS FOR THE PREPARATION OF (3R,3AS,6AR)-HEXAHYDROFURO [2,3-B]FURAN-3-YL (1S,2R)-3-[[(4-AMINOPHENYL) SULFONYL](ISOBUTYL) AMINO]-1-BENZYL-2-HYDROXYPROPYLCARBAMATE | JANSSEN R & D IRELAND (IE) | 2014-08-20 | — | — | EP | disclosed |
| EP-2766361-A1 | 8 - CARBAMOYL - 2 - (2,3- DI SUBSTITUTED PYRID - 6 - YL) -1,2,3,4 -TETRAHYDROISOQUINOLINE DERIVATIVES AS APOPTOSIS - INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Inc. (US) | 2014-08-20 | — | — | EP | disclosed |
| US-20140212421-A1 | METHODS AND COMPOSITIONS FOR ENHANCED DELIVERY OF MACROMOLECULES | ESBATECH, AN ALCON BIOMEDICAL RESEARCH UNIT LLC (CH) | 2014-07-31 | — | — | US | disclosed |
| EP-2757105-A1 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | Abbvie Inc. (US) | 2014-07-23 | — | — | EP | disclosed |
| US-20140187531-A1 | APOPTOSIS PROMOTERS | ABBVIE INC. (US) | 2014-07-03 | — | — | US | disclosed |
| EP-2507211-B1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2014-06-18 | — | — | EP | disclosed |
| US-20140113910-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2014-04-24 | — | — | US | disclosed |
| US-20140107119-A1 | BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | ABBVIE INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-8697074-B2 | Methods and compositions for enhanced delivery of macromolecules | ESBATECH, AN ALCON BIOMEDICAL RESEARCH UNIT LLC (CH) | 2014-04-15 | — | — | US | disclosed |
| US-20140088106-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-20140073640-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. | 2014-03-13 | — | — | US | disclosed |
| US-20140066621-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2014-03-06 | — | — | US | disclosed |
| US-20140057889-A1 | BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | ABBVIE INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-20140057890-A1 | BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | ABBVIE INC. (US) | 2014-02-27 | — | — | US | disclosed |
| EP-2308812-B1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBVIE BAHAMAS LTD (BS) | 2014-02-26 | — | — | EP | disclosed |
| WO-2014028381-A1 | APOPTOSIS-INDUCING AGENTS | ABBVIE INC. (US) | 2014-02-20 | — | — | WO | disclosed |
| EP-2697247-A1 | METHOD FOR THE RAPID CHEMOENZYMATIC GLYCOSYLATION OF CONJUGATES BETWEEN PEPTIDES AND HYDROPHILIC POLYMERS | Universität Wien (AT) | 2014-02-19 | — | — | EP | disclosed |
| US-8614318-B2 | Apoptosis promoters | ABBVIE INC. (US) | 2013-12-24 | — | — | US | disclosed |
| US-8586754-B2 | BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases | ABBVIE INC. (US) | 2013-11-19 | — | — | US | disclosed |
| US-8580794-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580981-B2 | Process for the preparation of (3R,3aS,6aR)-hexahydrofuro [2,3-b] furan-3-yl (1S,2R)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-hydroxypropylcarbamate | JANSSEN R&D IRELAND (IE) | 2013-11-12 | — | — | US | disclosed |
| US-20130296295-A1 | BCL-2 SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | ABBVIE INC (US) | 2013-11-07 | — | — | US | disclosed |
| WO-2013156525-A1 | NEW PROCESS FOR THE PRODUCTION AND PURIFICATION OF THE COLLAGENASE ENZYME FROM VIBRIO ALGINOLYTICUS | FIDIA FARMACEUTICI S.P.A. (IT) | 2013-10-24 | — | — | WO | disclosed |
| US-20130281384-A1 | LARAZOTIDE ACETATE COMPOSITIONS | INTERLUDE BIOPHARMA CO | 2013-10-24 | — | — | US | disclosed |
| US-8563735-B2 | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases | ABBVIE INC. (US) | 2013-10-22 | — | — | US | disclosed |
| EP-1757609-B1 | NOVEL WATER-SOLUBLE PRODRUG | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2013-10-16 | — | — | EP | disclosed |
| US-8557983-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-20130267514-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2013-10-10 | — | — | US | disclosed |
| US-20130267534-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2013-10-10 | — | — | US | disclosed |
| EP-2642999-A1 | METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS | AbbVie Inc. (US) | 2013-10-02 | — | — | EP | disclosed |
| US-8546399-B2 | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20130203960-A1 | MCR DENDRIMERS | Leibniz-Institut fur Pflanzenbiochemie (DE) | 2013-08-08 | — | — | US | disclosed |
| US-20130190488-A1 | APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130184278-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2013-07-18 | — | — | US | disclosed |
| US-8470829-B2 | Imidazolidine derivative and use thereof | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2013-06-25 | — | — | US | disclosed |
| US-8426422-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2013-04-23 | — | — | US | disclosed |
| WO-2013055895-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2013-04-18 | — | — | WO | disclosed |
| US-20130096121-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2013-04-18 | — | — | US | disclosed |
| WO-2013055897-A1 | 8 - CARBAMOYL - 2 - (2,3- DI SUBSTITUTED PYRID - 6 - YL) -1,2,3,4 -TETRAHYDROISOQUINOLINE DERIVATIVES AS APOPTOSIS - INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2013-04-18 | — | — | WO | disclosed |
| US-20130096120-A1 | APOPTOSIS-INDUCED AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2013-04-18 | — | — | US | disclosed |
| EP-2575463-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | Abbvie Inc. (US) | 2013-04-10 | — | — | EP | disclosed |
| EP-2576546-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | Abbvie Inc. (US) | 2013-04-10 | — | — | EP | disclosed |
| EP-2550258-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | Abbvie Inc. (US) | 2013-01-30 | — | — | EP | disclosed |
| US-8354404-B2 | Apoptosis promoters | ABBOTT LABORATORIES (US) | 2013-01-15 | — | — | US | disclosed |
| US-8343967-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBOTT LABORATORIES (US) | 2013-01-01 | — | — | US | disclosed |
| US-8338466-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBOTT LABORATORIES (US) | 2012-12-25 | — | — | US | disclosed |
| EP-1445249-B1 | NOVEL BENSOPHENONE DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2012-11-07 | — | — | EP | disclosed |
| WO-2012139777-A1 | METHOD FOR THE RAPID CHEMOENZYMATIC GLYCOSYLATION OF CONJUGATES BETWEEN PEPTIDES AND HYDROPHILIC POLYMERS | UNIVERSITÄT ZU KÖLN (DE) | 2012-10-18 | — | — | WO | disclosed |
| EP-2511264-A1 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | Abbott Laboratories (US) | 2012-10-17 | — | — | EP | disclosed |
| EP-2511289-A1 | Method for the rapid chemoenzymatic glycosylation of conjugates between peptides and hydrophilic polymers | Universität zu Köln (DE) | 2012-10-17 | — | — | EP | disclosed |
| EP-2507211-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | Abbott Laboratories (US) | 2012-10-10 | — | — | EP | disclosed |
| EP-2507229-A1 | SULFONAMIDE DERIVATIVES AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | Abbott Laboratories (US) | 2012-10-10 | — | — | EP | disclosed |
| US-RE43676-E1 | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-09-18 | — | — | US | disclosed |
| EP-2496574-A1 | IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION | Abbott Laboratories (US) | 2012-09-12 | — | — | EP | disclosed |
| US-20120214796-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. | 2012-08-23 | — | — | US | disclosed |
| EP-1614419-B1 | PREVENTIVE/REMEDY FOR RETINAL NERVE DISEASES CONTAINING ALKYL ETHER DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2012-08-08 | — | — | EP | disclosed |
| US-20120190688-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BRUNCKO MILAN (US) | 2012-07-26 | — | — | US | disclosed |
| WO-2012071374-A1 | METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS | ABBOTT LABORATORIES (US) | 2012-05-31 | — | — | WO | disclosed |
| US-8188077-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBOTT LABORATORIES (US) | 2012-05-29 | — | — | US | disclosed |
| US-20120129853-A1 | METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS | ABBOTT LABORATORIES (US) | 2012-05-24 | — | — | US | disclosed |
| US-8173811-B2 | Apoptosis promoters | ABBOTT LABORATORIES (US) | 2012-05-08 | — | — | US | disclosed |
| EP-2444412-A2 | Peptide production and purification process | SOLVAY SA (BE) | 2012-04-25 | — | — | EP | disclosed |
| WO-2012045195-A1 | PYRROLOPYRIMIDINES AS FAK AND ALK INHIBITERS FOR TREATMENT OF CANCERS AND OTHER DISEASES | ABBOTT LABORATORIES (US) | 2012-04-12 | — | — | WO | disclosed |
| WO-2012045194-A1 | BENZODIAZEPINONES AS FAK INHIBITORS FOR TREATMENT OF CANCER | ABBOTT LABORATORIES (US) | 2012-04-12 | — | — | WO | disclosed |
| EP-2435432-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | Abbott Laboratories (US) | 2012-04-04 | — | — | EP | disclosed |
| US-8129535-B2 | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-03-06 | — | — | US | disclosed |
| EP-1514542-B1 | Medicinal composition comprising Tacrine or Donepezil for improving brain function. | TOYAMA CHEMICAL CO LTD (JP) | 2012-02-22 | — | — | EP | disclosed |
| US-20120028925-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2012-02-02 | — | — | US | disclosed |
| US-8084607-B2 | Apoptosis promoters | ABBOTT LABORATORIES (US) | 2011-12-27 | — | — | US | disclosed |
| US-20110306615-A1 | NOVEL IMIDAZOLIDINE DERIVATIVE AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-12-15 | — | — | US | disclosed |
| WO-2011149492-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011150016-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-12-01 | — | — | WO | disclosed |
| EP-2389937-A1 | Medicinal composition for improving brain function | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-11-30 | — | — | EP | disclosed |
| US-8067406-B2 | Preventive/remedy for retinal nerve diseases containing alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-11-29 | — | — | US | disclosed |
| EP-2387560-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | Abbott Laboratories (US) | 2011-11-23 | — | — | EP | disclosed |
| EP-2387559-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | Abbott Laboratories (US) | 2011-11-23 | — | — | EP | disclosed |
| US-20110256129-A1 | APOPTOSIS PROMOTERS | ABBOTT LABORATORIES | 2011-10-20 | — | — | US | disclosed |
| EP-2376197-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | Abbott Laboratories (US) | 2011-10-19 | — | — | EP | disclosed |
| EP-2376480-A2 | SULFONAMIDE DERIVATIVES AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | Abbott Laboratories (US) | 2011-10-19 | — | — | EP | disclosed |
| US-8042193-B1 | Systems and methods for controlling data access by use of a universal anonymous identifier | Albright Associates (US) | 2011-10-18 | — | — | US | disclosed |
| US-8038956-B2 | Catalyzed soot filter manufacture and systems | BASF CORPORATION (US) | 2011-10-18 | — | — | US | disclosed |
| WO-2011119345-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-09-29 | — | — | WO | disclosed |
| US-20110237553-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-09-29 | — | — | US | disclosed |
| US-8022047-B2 | Combination anticancer agents | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-09-20 | — | — | US | disclosed |
| EP-2346877-A1 | PROCESS FOR THE PREPARATION OF (3R,3AS,6AR)-HEXAHYDROFURO [2,3-B]FURAN-3-YL (1S,2R)-3-[[(4-AMINOPHENYL) SULFONYL](ISOBUTYL) AMINO]-1-BENZYL-2-HYDROXYPROPYLCARBAMATE | Tibotec Pharmaceuticals (IE) | 2011-07-27 | — | — | EP | disclosed |
| EP-1481966-B1 | NOVEL ARYLAMIDINE DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2011-07-20 | — | — | EP | disclosed |
| US-7973161-B2 | Apoptosis promoters | ABBOTT LABORATORIES (US) | 2011-07-05 | — | — | US | disclosed |
| US-20110160468-A1 | PROCESS FOR THE PREPARATION OF (3R,3AS,6AR)-HEXAHYDROFURO [2,3-B] FURAN-3-YL (1S,2R)-3-[[(4-AMINOPHENYL) SULFONYL] (ISOBUTYL) AMINO]-1-BENZYL-2-HYDROXYPROPYLCARBAMATE | JANSSEN SCIENCES IRELAND UC (IE) | 2011-06-30 | — | — | US | disclosed |
| US-20110144112-A9 | APOPTOSIS PROMOTERS | ABBVIE INC. | 2011-06-16 | — | — | US | disclosed |
| WO-2011068561-A1 | SULFONAMIDE DERIVATIVES AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-06-09 | — | — | WO | disclosed |
| WO-2011068560-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-06-09 | — | — | WO | disclosed |
| US-20110135644-A1 | METHODS AND COMPOSITIONS FOR ENHANCED DELIVERY OF MACROMOLECULES | ESBATECH, AN ALCON BIOMEDICAL RESEARCH UNIT LLC (CH) | 2011-06-09 | — | — | US | disclosed |
| US-20110124632-A1 | IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION | ABBOTT LABORATORIES (US) | 2011-05-26 | — | — | US | disclosed |
| US-20110124628-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-05-26 | — | — | US | disclosed |
| US-20110112066-A1 | PREVENTIVE/REMEDY FOR RETINAL NERVE DISEASES CONTAINING ALKYL ETHER DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-05-12 | — | — | US | disclosed |
| WO-2011053476-A1 | IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION | ABBOTT LABORATORIES (US) | 2011-05-05 | — | — | WO | disclosed |
| US-RE42327-E1 | Medicinal compositions improving brain function and method for improving brain function | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-05-03 | — | — | US | disclosed |
| EP-2308812-A2 | N-acylsulfonamide apoptosis promoters | Abbott Laboratories (US) | 2011-04-13 | — | — | EP | disclosed |
| EP-2303230-A2 | METHODS AND COMPOSITIONS FOR ENHANCED DELIVERY OF MACROMOLECULES | ESBATech, an Alcon Biomedical Research Unit LLC (CH) | 2011-04-06 | — | — | EP | disclosed |
| US-7910593-B2 | Water-soluble prodrugs | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-03-22 | — | — | US | disclosed |
| US-7897594-B2 | Preventive/remedy for retinal nerve diseases containing alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-03-01 | — | — | US | disclosed |
| US-20110046349-A1 | PROCESS FOR THE PRODUCTION OF EXENATIDE AND OF AN EXENATIDE ANALOGUE | LONZA LTD. (CH) | 2011-02-24 | — | — | US | disclosed |
| WO-2010138588-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | WO | disclosed |
| US-20100305122-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100298323-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100298321-A1 | BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-11-25 | — | — | US | disclosed |
| US-7834053-B2 | Medicinal compositions improving brain function and method for improving brain function | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-11-16 | — | — | US | disclosed |
| US-20100280221-A1 | Peptide production and purification process | SOLVAY (SOCIETE ANONYME) (BE) | 2010-11-04 | — | — | US | disclosed |
| EP-1613762-B1 | PROCESS FOR PRODUCING ENANTIOPURE BETA-AMINO ACID DERIVATIVES, AND ENANTIOPURE BETA-AMINO ACID DERIVATIVES | SOLVAY (BE) | 2010-10-20 | — | — | EP | disclosed |
| US-20100240715-A1 | Apoptosis promoters | ABBOTT LABORATORIES | 2010-09-23 | — | — | US | disclosed |
| EP-1901755-B1 | NEW PHARMACEUTICAL COMPOSITIONS CONTAINING HYALURONIC ACID OR ITS DERIVATIVES AND COLLAGENASE FOR THE TOPICAL TREATMENT OF WOUNDS, BURNS AND ULCERS | FIDIA FARMACEUTICI (IT) | 2010-09-08 | — | — | EP | disclosed |
| EP-2222691-A2 | PEPTIDE PRODUCTION AND PURIFICATION PROCESS | SOLVAY (Société Anonyme) (BE) | 2010-09-01 | — | — | EP | disclosed |
| US-7772285-B2 | Benzophenone derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-08-10 | — | — | US | disclosed |
| US-7767684-B2 | Apoptosis promoters | ABBOTT LABORATORIES (US) | 2010-08-03 | — | — | US | disclosed |
| US-20100184750-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-07-22 | — | — | US | disclosed |
| US-20100184766-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-07-22 | — | — | US | disclosed |
| WO-2010083441-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-07-22 | — | — | WO | disclosed |
| WO-2010083442-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-07-22 | — | — | WO | disclosed |
| US-20100160322-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100152183-A1 | BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-06-17 | — | — | US | disclosed |
| WO-2010065865-A2 | BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010065824-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-06-10 | — | — | WO | disclosed |
| US-20100075941-A1 | PREVENTIVE/REMEDY FOR RETINAL NERVE DISEASES CONTAINING ALKYL ETHER DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-03-25 | — | — | US | disclosed |
| EP-1031569-B1 | SALT OF A 7-ISOINDOLINEQUINOLONECARBOXYLIC ACID DERIVATIVE, MONOHYDRATE THEREOF AND COMPOSITION CONTAINING THE SAME AS ACTIVE INGREDIENT | TOYAMA CHEMICAL CO LTD (JP) | 2010-03-17 | — | — | EP | disclosed |
| WO-2010023322-A1 | PROCESS FOR THE PREPARATION OF (3R,3AS,6AR)-HEXAHYDROFURO [2,3-B] FURAN-3-YL (1S,2R)-3-[[(4-AMINOPHENYL) SULFONYL] (ISOBUTYL) AMINO]-1-BENZYL-2-HYDROXYPROPYLCARBAMATE | TIBOTEC PHARMACEUTICALS (IE) | 2010-03-04 | — | — | WO | disclosed |
| US-20100022773-A1 | APOPTOSIS PROMOTERS | ABBVIE INC. | 2010-01-28 | — | — | US | disclosed |
| WO-2010003268-A2 | METHODS AND COMPOSITIONS FOR ENHANCED DELIVERY OF MACROMOLECULES | ESBATECH, AN ALCON BIOMEDICAL RESEARCH UNIT LLC (CH) | 2010-01-14 | — | — | WO | disclosed |
| US-7642260-B2 | N-acylsulfonamide derivatives; BCL-X1 protein inhibitors; anticarcinogenic agents; bladder cancer; for example, N-(4-(4-((4'-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)-propyl)amino)-3-nitrobenzenesulfonamide | ABBOTT LABORATORIES, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-7592476-B2 | Process for producing enantiopure β-amino acid derivatives, and enantiopure β-amino acid derivatives | SOLVAY S.A. (BE) | 2009-09-22 | — | — | US | disclosed |
| EP-1186594-B1 | N-ALKOXYALKYL-N,N-DIALKYLAMINE DERIVATIVES OR SALTS THEREOF, AND REMEDIES FOR NERVE DEGENERATION DISEASES CONTAINING THE SAME | TOYAMA CHEMICAL CO LTD (JP) | 2009-08-05 | — | — | EP | disclosed |
| US-20090171093-A1 | 3'-Fluoro-5'-hydroxythalidomide and derivatives thereof | FUJIMOTO CO. LTD. (JP) | 2009-07-02 | — | — | US | disclosed |
| US-20090149478-A1 | NOVEL COMBINATION ANTICANCER AGENTS | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2009-06-11 | — | — | US | disclosed |
| WO-2009065949-A2 | PEPTIDE PRODUCTION AND PURIFICATION PROCESS | Solvay (Société Anonyme) (BE) | 2009-05-28 | — | — | WO | disclosed |
| EP-2062909-A1 | Peptide production and purification process | SOLVAY (Société Anonyme) (BE) | 2009-05-27 | — | — | EP | disclosed |
| US-7538245-B2 | Process for the manufacture of an enantiopure compound | SOLVAY S.A. (BE) | 2009-05-26 | — | — | US | disclosed |
| US-20090118271-A1 | Preventive or Therapeutic Agents for Pancreatic Cancer, Ovarian Cancer, or Liver Cancer Comprising a Novel Water-Soluble Prodrug | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-05-07 | — | — | US | disclosed |
| US-20090118169-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL USE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-05-07 | — | — | US | disclosed |
| US-20090111992-A1 | ALKYL ETHER DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-04-30 | — | — | US | disclosed |
| US-7468443-B2 | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-12-23 | — | — | US | disclosed |
| US-20080206228-A1 | Medicament for topical use containing hyaluronic acid and proteolytic enzyme collagenase for use as wound healing agent | FIDIA FARMACEUTICI S.P.A (IT) | 2008-08-28 | — | — | US | disclosed |
| EP-1938823-A1 | AGENT FOR PREVENTING OR TREATING PANCREAS CANCER, OVARY CANCER OR LIVER CANCER CONTAINING NOVEL WATER-SOLUBLE PRODRUG | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-07-02 | — | — | EP | disclosed |
| EP-1925309-A1 | NOVEL ANTICANCER CONCOMITANT DRUG | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-05-28 | — | — | EP | disclosed |
| US-7371868-B2 | Processes for producing 7-isoindoline-quinolonecarboxylic acid derivative and its intermediate, as well as salt of 7-isoindoline-quinolonecarboxylic acid derivative, its hydrate and composition comprising the same as active ingredient | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-05-13 | — | — | US | disclosed |
| US-20080103126-A1 | Medicinal compositions improving brain function and method for improving brian function | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-05-01 | — | — | US | disclosed |
| EP-1901755-A1 | NEW PHARMACEUTICAL COMPOSITIONS CONTAINING HYALURONIC ACID AND COLLAGENASE FOR THE TOPICAL TREATMENT OF WOUNDS, BURNS AND ULCERS | FIDIA FARMACEUTICI S.p.A. (IT) | 2008-03-26 | — | — | EP | disclosed |
| US-7342043-B2 | synergistic antihypoxic mixture: acetylcholine esterase inhibitor (Donepezil and Tacrine) and neuroprotectant 1-[3-(2-(1-benzothiophen-5-yl)ethoxy)propyl]-3-azetidinol maleate; dysfunction of cerebral acetylcholine neurons in sequelae of cerebrovascular and senile dementia, Alzheimer's disease | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-03-11 | — | — | US | disclosed |
| US-20080027211-A1 | Enantiopure Heterocyclic Compound Useful for the Preparation of Peptides Which Can Be Potentially Used as Medicaments | SOLVAY S.A. (BE) | 2008-01-31 | — | — | US | disclosed |
| US-20080015157-A1 | Novel Water-Soluble Prodrugs | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-01-17 | — | — | US | disclosed |
| US-7314888-B1 | Compounds and medicinal use thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-01-01 | — | — | US | disclosed |
| US-7291617-B2 | Arylamidine derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-11-06 | — | — | US | disclosed |
| US-20070225506-A1 | PROCESSES FOR PRODUCING 7-ISOINDOLINE-QUINOLONECARBOXYLIC ACID DERIVATIVE AND ITS INTERMEDIATE, AS WELL AS SALT OF 7-ISOINDOLINE-QUINOLONECARBOXYLIC ACID DERIVATIVE, ITS HYDRATE AND COMPOSITION COMPRISING THE SAME AS ACTIVE INGREDIENT | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-09-27 | — | — | US | disclosed |
| EP-1802595-A1 | ENANTIOPURE HETEROCYCLIC COMPOUND USEFUL FOR THE PREPARATION OF PEPTIDES WHICH CAN BE POTENTIALLY USED AS MEDICAMENTS | Solvay SA (BE) | 2007-07-04 | — | — | EP | disclosed |
| EP-1437353-B1 | ALKYL ETHER DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2007-06-13 | — | — | EP | disclosed |
| US-20070123574-A1 | Methods for the preparation of benzoxazole sulfonamide compounds and intermediates thereof | DE KOCK HERMAN A | 2007-05-31 | — | — | US | disclosed |
| EP-1790640-A1 | NOVEL IMIDAZOLIDINE DERIVATIVE AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-05-30 | — | — | EP | disclosed |
| US-20070072860-A1 | N-acylsulfonamide derivatives; BCL-X1 protein inhibitors; anticarcinogenic agents; bladder cancer; for example, N-(4-(4-((4'-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)-propyl)amino)-3-nitrobenzenesulfonamide | ABBOTT LABORATORIES | 2007-03-29 | — | — | US | disclosed |
| EP-1757609-A1 | NOVEL WATER-SOLUBLE PRODRUG | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-02-28 | — | — | EP | disclosed |
| EP-1670773-B1 | METHODS FOR THE PREPARATION OF BENZOXAZOLE SULFONAMIDE COMPOUNDS AND INTERMEDIATES THEREOF | TIBOTEC PHARM LTD (IE) | 2007-02-07 | — | — | EP | disclosed |
| US-20070027326-A1 | Process for the manufacture of an enantiopure compound | SOLVAY S.A. (BE) | 2007-02-01 | — | — | US | disclosed |
| US-20070015787-A1 | Apoptosis promoters | ABBVIE INC. | 2007-01-18 | — | — | US | disclosed |
| WO-2007006484-A1 | NEW PHARMACEUTICAL COMPOSITIONS CONTAINING HYALURONIC ACID AND COLLAGENASE FOR THE TOPICAL TREATMENT OF WOUNDS, BURNS AND ULCERS | FIDIA FARMACEUTICI S.P.A. (IT) | 2007-01-18 | — | — | WO | disclosed |
| US-20060276673-A1 | Process for producing amino acid derivatives | SOLVAY S.A. (BE) | 2006-12-07 | — | — | US | disclosed |
| US-20060258657-A1 | Apoptosis promoters | ABBVIE INC. | 2006-11-16 | — | — | US | disclosed |
| EP-1070713-B1 | QUINOLONECARBOXYLIC ACID DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2006-10-18 | — | — | EP | disclosed |
| US-20060229310-A1 | Antibacterial compounds | ABBOTT LABORATORIES | 2006-10-12 | — | — | US | disclosed |
| US-20060211097-A1 | Process for producing enantiopure beta-amino acid derivatives, and enantiopure beta-amino acid derivatives | SOLVAY S.A. (BE) | 2006-09-21 | — | — | US | disclosed |
| US-20060205709-A1 | Preventive/remedy for retinal nerve diseases containing alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2006-09-14 | — | — | US | disclosed |
| US-20060194781-A1 | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2006-08-31 | — | — | US | disclosed |
| US-7087594-B2 | central nervous system disorders; regenerating nervous systems | TOYAMA CHEMICAL CO., LTD. (JP) | 2006-08-08 | — | — | US | disclosed |
| EP-1670773-A1 | METHODS FOR THE PREPARATION OF BENZOXAZOLE SULFONAMIDE COMPOUNDS AND INTERMEDIATES THEREOF | Tibotec Pharmaceuticals Ltd. (IE) | 2006-06-21 | — | — | EP | disclosed |
| US-20060128706-A1 | Apoptosis promoters | ABBVIE INC. | 2006-06-15 | — | — | US | disclosed |
| EP-1664084-A1 | PROCESS FOR THE MANUFACTURE OF AN ENANTIOPURE COMPOUND | SOLVAY (Société Anonyme) (BE) | 2006-06-07 | — | — | EP | disclosed |
| WO-2006037775-A1 | ENANTIOPURE HETEROCYCLIC COMPOUND USEFUL FOR THE PREPARATION OF PEPTIDES WHICH CAN BE POTENTIALLY USED AS MEDICAMENTS | Solvay (Société Anonyme) (BE) | 2006-04-13 | — | — | WO | disclosed |
| EP-1613762-A2 | PROCESS FOR PRODUCING ENANTIOPURE BETA-AMINO ACID DERIVATIVES, AND ENANTIOPURE BETA-AMINO ACID DERIVATIVES | SOLVAY (Société Anonyme) (BE) | 2006-01-11 | — | — | EP | disclosed |
| EP-1614419-A1 | PREVENTIVE/REMEDY FOR RETINAL NERVE DISEASES CONTAINING ALKYL ETHER DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2006-01-11 | — | — | EP | disclosed |
| EP-1613586-A1 | PROCESS FOR PRODUCING AMINO ACID DERIVATIVES | SOLVAY (BE) | 2006-01-11 | — | — | EP | disclosed |
| US-20050250843-A1 | Medicinal compositions improving brain function and method for improving brain function | TOYAMA CHEMICAL CO., LTD. (JP) | 2005-11-10 | — | — | US | disclosed |
| US-20050203301-A1 | Processes for producing 7-isoindoline-quinolone carboxylic acid derivative and its intermediate, as well as salt of 7-isoindoline-quinolonecarboxylic acid derivative, its hydrate and composition comprising the same as active ingredient | TOYAMA CHEMICAL CO., LTD. (JP) | 2005-09-15 | — | — | US | disclosed |
| US-20050159427-A1 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES | 2005-07-21 | — | — | US | disclosed |
| US-20050118605-A9 | Oligomeric compounds having modified bases for binding to adenine and guanine and their use in gene modulation | ISIS PHARMACEUTICALS, INC. | 2005-06-02 | — | — | US | disclosed |
| US-20050113400-A1 | Inhibitors of transcription factor AP-1; autoimmune diseases; rheumatoid arthritis; high safety and excellent pharmacokinetics in vivo | SHUNICHI SHIOZAWA (JP) | 2005-05-26 | — | — | US | disclosed |
| US-20050113424-A1 | Novel arylamidine derivative or salt thereof | TOYAMA CHEMICAL CO., LTD (JP) | 2005-05-26 | — | — | US | disclosed |
| EP-1295890-B1 | Novel pyrazine derivatives or salts thereof, pharmaceutical composition containing the same, and production intermediates thereof | TOYAMA CHEMICAL CO LTD (JP) | 2005-04-27 | — | — | EP | disclosed |
| WO-2005030739-A1 | METHODS FOR THE PREPARATION OF BENZOXAZOLE SULFONAMIDE COMPOUNDS AND INTERMEDIATES THEREOF | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2005-04-07 | — | — | WO | disclosed |
| US-20050070521-A1 | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2005-03-31 | — | — | US | disclosed |
| WO-2005023838-A1 | PROCESS FOR THE MANUFACTURE OF AN ENANTIOPURE COMPOUND | Solvay (Société Anonyme) (BE) | 2005-03-17 | — | — | WO | disclosed |
| EP-1514542-A1 | MEDICINAL COMPOSITIONS IMPROVING BRAIN FUNCTION AND METHOD FOR IMPROVING BRAIN FUNCTION | TOYAMA CHEMICAL CO., LTD. (JP) | 2005-03-16 | — | — | EP | disclosed |
| US-20050037370-A1 | Oligomeric compounds having modified bases for binding to adenine and guanine and their use in gene modulation | BAKER BRENDA F (US) | 2005-02-17 | — | — | US | disclosed |
| US-20050032069-A1 | Oligomeric compounds having modified bases for binding to adenine and guanine and their use in gene modulation | ISIS PHARMACEUTICALS, INC. | 2005-02-10 | — | — | US | disclosed |
| EP-1256588-B1 | NOVEL PYRAZINE DERIVATIVES OR SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS CONTAINING THE DERIVATIVES OR THE SALTS AND INTERMEDIATES FOR THE PREPARATION OF BOTH | TOYAMA CHEMICAL CO LTD (JP) | 2005-02-02 | — | — | EP | disclosed |
| EP-1481966-A1 | NOVEL ARYLAMIDINE DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2004-12-01 | — | — | EP | disclosed |
| EP-1106609-B1 | Aminoalcohol derivative and medicament comprising the same | SEIKAGAKU KOGYO CO LTD (JP) | 2004-12-01 | — | — | EP | disclosed |
| US-20040235761-A1 | Novel virus proliferaton inhibition/virucidal method and novel pyradine nucleotide/pyradine nucleoside analogue | TOYAMA CHEMICAL CO., LTD. (JP) | 2004-11-25 | — | — | US | disclosed |
| WO-2004087940-A2 | PROCESS FOR PRODUCING ENANTIOPURE β-AMINO ACID DERIVATIVES, AND ENANTIOPURE β-AMINO ACID DERIVATIVES | Solvay (Société Anonyme) (BE) | 2004-10-14 | — | — | WO | disclosed |
| WO-2004087661-A1 | PROCESS FOR THE ENANTIOSELECTIVE PRODUCTION OF AN AMINO ACID DERIVATIVE COMPRISING AT LEAST ONE NITROGENOUS HETEROCYCLE | Solvay (Société Anonyme) (BE) | 2004-10-14 | — | — | WO | disclosed |
| WO-2004087638-A1 | PROCESS FOR PRODUCING AMINO ACID DERIVATIVES | SOLVAY (BE) | 2004-10-14 | — | — | WO | disclosed |
| US-6800629-B2 | VIRICIDES | TOYAMA CHEMICAL CO., LTD. (JP) | 2004-10-05 | — | — | US | disclosed |
| US-6797726-B1 | N-alkoxyalkyl-N,N-dialkylamine derivatives or salts thereof, and remedies for nerve degeneration diseases containing the same | TOYAMA CHEMICAL CO., LTD. (JP) | 2004-09-28 | — | — | US | disclosed |
| EP-1445249-A1 | NOVEL BENSOPHENONE DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2004-08-11 | — | — | EP | disclosed |
| EP-1437353-A1 | ALKYL ETHER DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2004-07-14 | — | — | EP | disclosed |
| WO-2004044245-A1 | OLIGOMERIC COMPOUNDS HAVING MODIFIED BASES FOR BINDING TO ADENINE AND GUANINE AND THEIR USE IN GENE MODULATION | ISIS PHARMACEUTICALS, INC. (US) | 2004-05-27 | — | — | WO | disclosed |
| EP-1417967-A1 | NOVEL VIRUS PROLIFERATION INHIBITION/VIRUCIDAL METHOD AND NOVEL PYRADINE NUCLEOTIDE/PYRADINE NUCLEOSIDE ANALOGUE | TOYAMA CHEMICAL CO., LTD. (JP) | 2004-05-12 | — | — | EP | disclosed |
| US-6613537-B2 | Diagnosis of diabetes | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2003-09-02 | — | — | US | disclosed |
| EP-0775702-B1 | NOVEL QUINOLONE- OR NAPHTHYRIDONECARBOXYLIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2003-07-23 | — | — | EP | disclosed |
| US-20030130213-A1 | Novel pyrazine derivatives or salts thereof, pharmaceutical composition containing the same, and production intermediates thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2003-07-10 | — | — | US | disclosed |
| EP-0973756-B1 | THIODEPSIPEPTIDES FOR COMBATING ENDOPARASITES AND A METHOD FOR PRODUCING THE SAME | BAYER AG (DE) | 2003-03-26 | — | — | EP | disclosed |
| EP-1295890-A1 | Novel pyrazine derivatives or salts thereof, pharmaceutical composition containing the same, and production intermediates thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2003-03-26 | — | — | EP | disclosed |
| US-20030008814-A1 | Pseudomycin phosphate prodrugs | ELI LILLY AND COMPANY | 2003-01-09 | — | — | US | disclosed |
| EP-0882725-B1 | QUINOLONECARBOXYLIC ACID DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2002-12-18 | — | — | EP | disclosed |
| US-6482835-B2 | SUCH AS (R)-1-CYCLOPROPYL-8-DIFLUOROMETHOXY-7-(1-METHYL-2,3-DIHYDRO-1H-5-ISOINDOLYL)-4-OXO-1,4-DIHYDRO-3-QUINOLINECARBOXYL IC ACID METHANESULFONATE; CHEMICAL INTERMEDIATES; BACTERICIDES; CATALYSIS | TOYAMA CHEMICAL CO., LTD. (JP) | 2002-11-19 | — | — | US | disclosed |
| EP-1256588-A1 | NOVEL PYRAZINE DERIVATIVES OR SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS CONTAINING THE DERIVATIVES OR THE SALTS AND INTERMEDIATES FOR THE PREPARATION OF BOTH | TOYAMA CHEMICAL CO., LTD. (JP) | 2002-11-13 | — | — | EP | disclosed |
| US-6441189-B1 | WHICH REDUCES RACEMIZATION; (4R)-4-(HYDROXYMETHYL)-1,3-OXAZOLIDIN-2-ONE BY REDUCTION AND BASIFICATION OF THE CORRESPONDING 4-PROTECTED CARBOXY ESTER | ABBOTT LABORATORIES | 2002-08-27 | — | — | US | disclosed |
| EP-1226146-A2 | QUINOLINE AND NAPHTHYRIDINE CARBOXYLIC ACID ANTIBACTERIALS | ABBOTT LABORATORIES (US) | 2002-07-31 | — | — | EP | disclosed |
| US-6407064-B2 | A MORPHOLINO RING CONTAINING ALKYLAMINOALCOHOL DERIVATIVE OR SALTS USEFUL FOR TREATING NEURONAL DISEASES AND AN AGENT FOR PROTECTING BRAIN | SEIKAGAKU CORPORATION (JP) | 2002-06-18 | — | — | US | disclosed |
| US-6384065-B1 | CONTROL THE FUNCTIONS OF PROTEINS SUCH AS ENZYMES AND RECEPTOR FORTREATING INFLAMMATORY DISEASES SUCH AS RHEUMATOID ARTHRITIS, | TOYAMA CHEMICAL CO., LTD. (JP) | 2002-05-07 | — | — | US | disclosed |
| EP-1200460-A1 | PSEUDOMYCIN N-ACYL SIDE-CHAIN ANALOGS | ELI LILLY AND COMPANY (US) | 2002-05-02 | — | — | EP | disclosed |
| US-20020052511-A1 | Process for the preparation of matrix metalloproteinase inhibitors | BAILEY ANNE E (US) | 2002-05-02 | — | — | US | disclosed |
| US-20020049328-A1 | Processes for producing 7-isoindoline-quinolonecarboxylic acid derivative and its intermediate, as well as salt of 7-isoindoline-quinolonecarboxylic acid derivative, its hydrate and composition comprising the same as active ingredient | TOYAMA CHEMICAL CO., LTD. (JP) | 2002-04-25 | — | — | US | disclosed |
| US-20020049223-A1 | Quinoline and naphthyridine carboxylic acid antibacterials | ABBOTT LABORATORIES | 2002-04-25 | — | — | US | disclosed |
| EP-1198472-A1 | AMINE-MODIFIED PSEUDOMYCIN COMPOUNDS | ELI LILLY AND COMPANY (US) | 2002-04-24 | — | — | EP | disclosed |
| EP-1198470-A1 | PSEUDOMYCIN PRODRUGS | ELI LILLY AND COMPANY (US) | 2002-04-24 | — | — | EP | disclosed |
| EP-1192142-A1 | CYCLO-IMINO DEPSIPEPTIDES AND THEIR UTILIZATION IN CONTROLLING ENDOPARASITES | Bayer Aktiengesellschaft (DE) | 2002-04-03 | — | — | EP | disclosed |
| EP-1186594-A1 | N-ALKOXYALKYL-N,N-DIALKYLAMINE DERIVATIVES OR SALTS THEREOF, AND REMEDIES FOR NERVE DEGENERATION DISEASES CONTAINING THE SAME | TOYAMA CHEMICAL CO., LTD. (JP) | 2002-03-13 | — | — | EP | disclosed |
| US-20020028464-A1 | Pyrrolopyridinium derivatives | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2002-03-07 | — | — | US | disclosed |
| US-20020019539-A1 | Process for the preparation of matrix metalloproteinase inhibitors | ABBOTT LABORATORIES | 2002-02-14 | — | — | US | disclosed |
| US-6337399-B1 | CONDENSATION OF ISOINDOLE WITH BORATE GROUP WITH QUINOLONE CARBOXYLIC ACID | TOYAMA CHEMICAL CO., LTD. (JP) | 2002-01-08 | — | — | US | disclosed |
| US-6335447-B1 | BACTERICIDES | TOYAMA CHEMICAL CO., LTD. (JP) | 2002-01-01 | — | — | US | disclosed |
| EP-0644890-B1 | OLIGONUCLEOTIDE-POLYAMIDE CONJUGATES | HOWARD FLOREY INST OF BR EX PH (AU) | 2001-12-05 | — | — | EP | disclosed |
| WO-2001074792-A2 | PROCESS FOR THE PREPARATION OF MATRIX METALLOPROTEINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2001-10-11 | — | — | WO | disclosed |
| EP-1130021-A2 | Pyrrolopyridinium derivatives | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2001-09-05 | — | — | EP | disclosed |
| EP-0630374-B1 | IMIDAZOLE, TRIAZOLE AND TETRAZOLE DERIVATIVES | MERCK SHARP & DOHME (GB) | 2001-09-05 | — | — | EP | disclosed |
| EP-1127869-A1 | NOVEL COMPOUNDS AND MEDICINAL USE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2001-08-29 | — | — | EP | disclosed |
| US-6265537-B1 | CYCLIC COMPOUNDS; NEMATOCIDES FOR HUMANS AND ANIMALS | BAYER AKTIENGESELLSCHAFT (DE) | 2001-07-24 | — | — | US | disclosed |
| WO-2001041534-A2 | PSEUDOMYCIN PHOSPHATE PRODRUGS | ELI LILLY AND COMPANY (US) | 2001-06-14 | — | — | WO | disclosed |
| US-20010003741-A1 | Aminoalcohol derivative and medicament comprising the same | SEIKAGAKU CORPORATION (JP) | 2001-06-14 | — | — | US | disclosed |
| EP-1106609-A2 | Aminoalcohol derivative and medicament comprising the same | SEIKAGAKU CORPORATION (JP) | 2001-06-13 | — | — | EP | disclosed |
| WO-2001032655-A2 | QUINOLINE AND NAPHTHYRIDINE CARBOXYLIC ACID ANTIBACTERIALS | ABBOTT LABORATORIES (US) | 2001-05-10 | — | — | WO | disclosed |
| EP-1076056-A1 | NOVEL SPIRO COMPOUNDS OR SALTS THEREOF AND PREVENTIVES/REMEDIES FOR AUTOIMMUNE DISEASES AND AP-1 INHIBITORS CONTAINING THE SAME | TOYAMA CHEMICAL CO., LTD. (JP) | 2001-02-14 | — | — | EP | disclosed |
| WO-2001005816-A1 | AMINE-MODIFIED PSEUDOMYCIN COMPOUNDS | ELI LILLY AND COMPANY (US) | 2001-01-25 | — | — | WO | disclosed |
| WO-2001005814-A1 | PSEUDOMYCIN N-ACYL SIDE-CHAIN ANALOGS | ELI LILLY AND COMPANY (US) | 2001-01-25 | — | — | WO | disclosed |
| WO-2001005813-A1 | PSEUDOMYCIN PRODRUGS | ELI LILLY AND COMPANY (US) | 2001-01-25 | — | — | WO | disclosed |
| EP-1070713-A1 | QUINOLONECARBOXYLIC ACID DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2001-01-24 | — | — | EP | disclosed |
| WO-2000076985-A1 | CYCLO-IMINO DEPSIPEPTIDES AND THEIR UTILIZATION IN CONTROLLING ENDOPARASITES | BAYER AKTIENGESELLSCHAFT (DE) | 2000-12-21 | — | — | WO | disclosed |
| US-6153613-A | 2,3-diketopiperazine derivatives or their salts | TOYOMA CHEMICAL CO., LTD. (JP) | 2000-11-28 | — | — | US | disclosed |
| US-6127339-A | AND REMOVING IT FROM A BODY FLUID; ABSORBENT COMPRISING A PEPTIDE OF AMINO ACID SEQUENCE WHICH INCLUDES PHENYLALANINE OR TRYPTOPHAN AND ARGININE OR LYSINE, HAS SPECIFIED ELECTRICAL CHARGE, AND IS BONDED TO A WATER INSOLUBLE CARRIER | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 2000-10-03 | — | — | US | disclosed |
| EP-1031569-A1 | PROCESSES FOR PRODUCING 7-ISOINDOLINEQUINOLONECARBOXYLIC DERIVATIVES AND INTERMEDIATES THEREFOR, SALTS OF 7-ISOINDOLINEQUINOLONECARBOXYLIC ACIDS, HYDRATES THEREOF, AND COMPOSITION CONTAINING THE SAME AS ACTIVE INGREDIENT | TOYAMA CHEMICAL CO., LTD. (JP) | 2000-08-30 | — | — | EP | disclosed |
| EP-0563797-B1 | Pyridinium derivatives | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 2000-07-05 | — | — | EP | disclosed |
| EP-0695750-B1 | Naphthyridinium derivative, method for its production; antibody against said derivative and the use of said antibody | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 2000-03-01 | — | — | EP | disclosed |
| US-6025370-A | METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS | TOYAMA CHEMICAL CO., LTD. (JP) | 2000-02-15 | — | — | US | disclosed |
| EP-0973756-A1 | THIODEPSIPEPTIDES FOR COMBATING ENDOPARASITES AND A METHOD FOR PRODUCING THE SAME | BAYER AG (DE) | 2000-01-26 | — | — | EP | disclosed |
| US-6013434-A | Oligonucleotide-polyamide conjugates | HOWARD FLOREY INSTITUTE OF EXPERIMENTAL PHYSIOLOGY AND MEDICINE (AU) | 2000-01-11 | — | — | US | disclosed |
| US-5965770-A | CHIRAL PURITY; SYNTHETIC PEPTIDES USED AS REAGENTS FOR ANALYTICAL TESTS, SWEETENING AGENTS, SYNTHETIC HORMONES | SOLVAY (BE) | 1999-10-12 | — | — | US | disclosed |
| US-5935952-A | ANTIBACTERIAL AGENT | TOYAMA CHEMICAL CO., LTD. (JP) | 1999-08-10 | — | — | US | disclosed |
| US-5912352-A | CATALYTIC REDUCTION OF HYDRAZIDE TO HYDRAZINE DERIVATIVE IN PRESENCE OF COMPLEX HYDRIDE; ACYL MIGRATION; HYDROGENATION; CATALYST SELECTIVITY | NOVARTIS FINANCE CORPORATION (US) | 1999-06-15 | — | — | US | disclosed |
| US-5912232-A | ADMINISTERING PEPTIDES HAVING ANTAGONIST ACTIVITY FOR ALPHA CHEMOKINES, FOR TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 1999-06-15 | — | — | US | disclosed |
| EP-0581538-B1 | 4-Substituted 1,2,4-triazole derivatives | MERCK SHARP & DOHME (GB) | 1999-03-03 | — | — | EP | disclosed |
| US-5877174-A | ANTICOAGULANTS | TOYAMA CHEMICAL CO., LTD. (JP) | 1999-03-02 | — | — | US | disclosed |
| US-5877276-A | AMINO ACID SEQUENCE OF SYNTHETIC, LOW MOLECULAR WEIGHT PROTEIN; ANTICARCINOGENIC/ANTITUMOR AGENTS; BACTERICIDES; FUNGICIDES; VIRICIDES; PARASITICIDES | THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 1999-03-02 | — | — | US | disclosed |
| EP-0882725-A1 | QUINOLONECARBOXYLIC ACID DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 1998-12-09 | — | — | EP | disclosed |
| US-5834499-A | TREATING GASTROINTESTINAL DISORDERS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1998-11-10 | — | — | US | disclosed |
| WO-1998043965-A1 | THIODEPSIPEPTIDES FOR COMBATING ENDOPARASITES AND A METHOD FOR PRODUCING THE SAME | BAYER AKTIENGESELLSCHAFT (DE) | 1998-10-08 | — | — | WO | disclosed |
| US-5776948-A | BACTERICIDE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 1998-07-07 | — | — | US | disclosed |
| US-5770692-A | METHOD OF INTRODUCING UREIDO GROUPS INTO PEPTIDES WHILE PRESERVING STEREOCHEMISTRY | PEPTISYNTHA (BE) | 1998-06-23 | — | — | US | disclosed |
| EP-0838472-A1 | PEPTIDES BINDING TO LOW-DENSITY LIPOPROTEINS | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1998-04-29 | — | — | EP | disclosed |
| EP-0624163-B1 | CYCLIC CALCITONIN DERIVATIVES AND METHOD FOR THEIR PRODUCTION | SMITHKLINE BEECHAM FARMA (IT) | 1998-03-25 | — | — | EP | disclosed |
| WO-1997046514-A1 | PROCESS FOR THE PREPARATION OF HYDRAZINE DERIVATIVES USEFUL AS INTERMEDIATES FOR THE PREPARATION OF PEPTIDE ANALOGUES | NOVARTIS AG (CH) | 1997-12-11 | — | — | WO | disclosed |
| US-5688760-A | BONE DISORDERS TREATED WITH PARATHYROID HORMONE RELATED PROTEINS OR ADENYLATE CYCLASE STIMULATING FACTOR | GENENTECH, INC. (US) | 1997-11-18 | — | — | US | disclosed |
| US-5686251-A | Naphthyridinium derivatives | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 1997-11-11 | — | — | US | disclosed |
| EP-0805149-A1 | NOVEL 2,3-DIKETOPIPERAZINE DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 1997-11-05 | — | — | EP | disclosed |
| EP-0775702-A1 | NOVEL QUINOLONE- OR NAPHTHYRIDONECARBOXYLIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 1997-05-28 | — | — | EP | disclosed |
| US-5627156-A | LOW MOLECULAR WEIGHT; TREATING INFECTIONS, NEOPLASTIC DISEASES | UNIVERSITY OF NEBRASKA BOARD OF REGENTS (US) | 1997-05-06 | — | — | US | disclosed |
| US-5620972-A | Substituted benzene derivatives | MERCK SHARP & DOHME LTD. (GB) | 1997-04-15 | — | — | US | disclosed |
| EP-0386839-B1 | Tetrahydroquinoline derivatives useful for neurodegenerative disorders | MERCK SHARP & DOHME (GB) | 1997-01-15 | — | — | EP | disclosed |
| EP-0749966-A1 | 5-HT 3 RECEPTOR AGONIST, NOVEL THIAZOLE DERIVATIVE, AND INTERMEDIATE THEREFOR | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1996-12-27 | — | — | EP | disclosed |
| US-5554629-A | HEADACHES | MERCK, SHARP & DOHME LTD. (GB) | 1996-09-10 | — | — | US | disclosed |
| US-5552540-A | NONRADIOACTIVE LABELS | HOWARD FLOREY INSTITUTE OF EXPERIMENTAL PHYSIOLOGY AND MEDICINE (AU) | 1996-09-03 | — | — | US | disclosed |
| EP-0574028-B1 | Dipeptide analogs of aspertame and process to prepare them as well as a new preparation of aspertame | HAMPSHIRE CHEMICAL CORP (US) | 1996-08-28 | — | — | EP | disclosed |
| US-5514682-A | HEADACHE | MERCK SHARP & DOHME LIMITED (GB) | 1996-05-07 | — | — | US | disclosed |
| US-5510362-A | VASOCONSTRUCTION | MERCK, SHARP AND DOHME LIMITED (GB) | 1996-04-23 | — | — | US | disclosed |
| WO-1996009062-A1 | POLYPEPTIDE AGONISTS AND ANTAGONISTS OF HUMAN INTERLEUKIN-8 | UNIVERSITY OF NEBRASKA BOARD OF REGENTS (US) | 1996-03-28 | — | — | WO | disclosed |
| EP-0695750-A1 | Naphthyridinium derivative, method for its production; antibody against said derivative and the use of said antibody | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 1996-02-07 | — | — | EP | disclosed |
| EP-0362941-B1 | 4-Methyl and 4-ethyl substituted pyrrolidin-2-ones | MERCK SHARP & DOHME (GB) | 1995-12-20 | — | — | EP | disclosed |
| EP-0664288-A1 | FLUOROQUINOLINE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 1995-07-26 | — | — | EP | disclosed |
| EP-0389437-B1 | Luciferin derivatives | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 1995-05-24 | — | — | EP | disclosed |
| EP-0640085-A1 | FUSED IMIDAZOLE AND TRIAZOLE DERIVATIVES AS 5-HT1 RECEPTOR AGONISTS | MERCK SHARP & DOHME LTD. (GB) | 1995-03-01 | — | — | EP | disclosed |
| EP-0630374-A1 | IMIDAZOLE, TRIAZOLE AND TETRAZOLE DERIVATIVES | MERCK SHARP & DOHME LTD. (GB) | 1994-12-28 | — | — | EP | disclosed |
| US-5376748-A | Antiepileptic agents, anticonvulsants | MERCK SHARP & DOHME LIMITED (GB) | 1994-12-27 | — | — | US | disclosed |
| EP-0624163-A1 | CYCLIC CALCITONIN DERIVATIVES AND METHOD FOR THEIR PRODUCTION | Smithkline Beecham Farmaceutici S.p.A. (IT) | 1994-11-17 | — | — | EP | disclosed |
| EP-0366685-B1 | NUCLEOSIDE DERIVATIVES | FLOREY HOWARD INST (AU) | 1994-10-19 | — | — | EP | disclosed |
| US-5338850-A | Diagnosis of diabetes and aging-related diseases | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 1994-08-16 | — | — | US | disclosed |
| US-5324733-A | Selective ligands at sigma recognition sites | MERCK SHARPE & DOHME LTD. | 1994-06-28 | — | — | US | disclosed |
| EP-0220923-B1 | Dipeptides and process | GRACE W R & CO (US) | 1994-04-27 | — | — | EP | disclosed |
| US-5294618-A | Psychological disorders | MERCK SHARP & DOHME LIMITED (GB) | 1994-03-15 | — | — | US | disclosed |
| EP-0414289-B1 | Spirocyclic antipsychotic agents | MERCK SHARP & DOHME (GB) | 1994-02-23 | — | — | EP | disclosed |
| WO-1994003446-A1 | 4-SUBSTITUTED 1,2,4-TRIAZOLE DERIVATIVES | MERCK SHARP & DOHME LIMITED (GB) | 1994-02-17 | — | — | WO | disclosed |
| EP-0581538-A1 | 4-Substituted 1,2,4-triazole derivatives | MERCK SHARP & DOHME LTD. (GB) | 1994-02-02 | — | — | EP | disclosed |
| EP-0574028-A1 | Dipeptide analogs of aspertame and process to prepare them as well as a new preparation of aspertame | HAMPSHIRE CHEMICAL CORP. (US) | 1993-12-15 | — | — | EP | disclosed |
| WO-1993023396-A1 | FUSED IMIDAZOLE AND TRIAZOLE DERIVATIVES AS 5-HT1 RECEPTOR AGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 1993-11-25 | — | — | WO | disclosed |
| EP-0566824-A1 | Enzymatic peptide synthesis | F. HOFFMANN-LA ROCHE AG (CH) | 1993-10-27 | — | — | EP | disclosed |
| EP-0272564-B1 | Enzyme mediated coupling reactions | HAMPSHIRE CHEMICAL CORP (US) | 1993-10-20 | — | — | EP | disclosed |
| US-5254561-A | Tricyclic antipsychotic agents | MERCK SHARP & DOHME LIMITED (GB) | 1993-10-19 | — | — | US | disclosed |
| EP-0563797-A1 | Pyridinium derivatives | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 1993-10-06 | — | — | EP | disclosed |
| WO-1993018029-A1 | IMIDAZOLE, TRIAZOLE AND TETRAZOLE DERIVATIVES | MERCK SHARP & DOHME LIMITED (GB) | 1993-09-16 | — | — | WO | disclosed |
| WO-1993015106-A1 | CYCLIC CALCITONINE DERIVATIVES AND METHOD FOR THEIR PRODUCTION | SMITHKLINE BEECHAM FARMACEUTICI S.P.A. (IT) | 1993-08-05 | — | — | WO | disclosed |
| US-5231102-A | Tetrahydroquinoline derivatives useful for neurodegenerative disorders | MERCK SHARP & DOHME, LTD. (GB) | 1993-07-27 | — | — | US | disclosed |
| US-5219860-A | Neuroleptic agents | MERCK SHARP & DOHME LIMITED (GB) | 1993-06-15 | — | — | US | disclosed |
| EP-0181121-B1 | NOVEL POLYPEPTIDE AND PROCESS FOR PRODUCING THE SAME | MITSUBISHI PETROCHEMICAL CO., LTD. (JP) | 1992-12-30 | — | — | EP | disclosed |
| EP-0318091-B1 | RESOLVED AMINO PYRROLIDINE NEUROPROTECTIVE AGENTS | MERCK SHARP & DOHME LTD. (GB) | 1992-12-09 | — | — | EP | disclosed |
| EP-0213914-B1 | CLAVAM DERIVATIVES, PREPARATION AND INTERMEDIATES THEREFOR | BEECHAM GROUP PLC (GB) | 1992-11-11 | — | — | EP | disclosed |
| US-5144027-A | Cephalosporins, process for producing the same, intermediates thereof and process for producing the intermediates | TOYAMA CHEMICAL CO., LTD. (JP) | 1992-09-01 | — | — | US | disclosed |
| US-5130241-A | CLAVAM DERIVATIVES AND ITS ENZYMATIC PREPARATION | BEECHAM GROUP PLC (GB) | 1992-07-14 | — | — | US | disclosed |
| US-5128069-A | Luciferin derivatives | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 1992-07-07 | — | — | US | disclosed |
| US-5120746-A | Inhibit gastric acid secretion | TOYAMA CHEMICAL CO., LTD. (JP) | 1992-06-09 | — | — | US | disclosed |
| US-5116741-A | Subtilisin catalyzed acylation of nucleosides | GENEX CORPORATION (US) | 1992-05-26 | — | — | US | disclosed |
| EP-0463691-A2 | Tricyclic sigma ligands | MERCK SHARP & DOHME LTD. (GB) | 1992-01-02 | — | — | EP | disclosed |
| EP-0114787-B1 | PEPTIDE DERIVATIVES | CIBA-GEIGY AG (CH) | 1991-09-25 | — | — | EP | disclosed |
| EP-0445974-A2 | Spirocyclic antipsychotic agents | MERCK SHARP & DOHME LTD. (GB) | 1991-09-11 | — | — | EP | disclosed |
| US-5002872-A | Peptides, Liquid Phase, Acetonitrile, Water | W. R. GRACE & CO.-CONN. (US) | 1991-03-26 | — | — | US | disclosed |
| EP-0366685-A4 | NUCLEOSIDE DERIVATIVES | — | 1991-03-20 | — | — | EP | disclosed |
| US-4987132-A | PLATELET ACTIVATING FACTOR ANTAGONISTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1991-01-22 | — | — | US | disclosed |
| EP-0389437-A1 | Luciferin derivatives | NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) | 1990-09-26 | — | — | EP | disclosed |
| EP-0386839-A2 | Tetrahydroquinoline derivatives useful for neurodegenerative disorders | MERCK SHARP & DOHME LTD. (GB) | 1990-09-12 | — | — | EP | disclosed |
| US-4931555-A | CEPHALOSPORINS | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1990-06-05 | — | — | US | disclosed |
| US-4925867-A | MUSCLE RELAXANTS, PREVENTION OF NEURODEGENERATIVE DISEASES | MERCK SHARP & DOHME LTD. (GB) | 1990-05-15 | — | — | US | disclosed |
| EP-0366685-A1 | NUCLEOSIDE DERIVATIVES. | FLOREY HOWARD INST (AU) | 1990-05-09 | — | — | EP | disclosed |
| US-4923882-A | Novel amine derivatives, salts thereof and an anti-ulcer agent containing the same | TOYAMA CHEMICAL CO., LTD. (JP) | 1990-05-08 | — | — | US | disclosed |
| US-4921839-A | Erythromycin a 11,12-carbonate 9-oxime derivatives | BEECHAM GROUP P.L.C. (GB) | 1990-05-01 | — | — | US | disclosed |
| EP-0362941-A2 | 4-Methyl and 4-ethyl substituted pyrrolidin-2-ones | MERCK SHARP & DOHME LTD. (GB) | 1990-04-11 | — | — | EP | disclosed |
| EP-0201166-B1 | ERYTHROMYCIN DERIVATIVES | BEECHAM GROUP PLC (GB) | 1990-02-07 | — | — | EP | disclosed |
| US-4879381-A | ANTIBIOTICS | TOYOMA CHEMICAL COMPANY, LTD. (JP) | 1989-11-07 | — | — | US | disclosed |
| US-4873359-A | Process for preparing as partyl-phenylalanine dipeptides | W. R. GRACE & CO. - CONN. (US) | 1989-10-10 | — | — | US | disclosed |
| US-4863953-A | [3R]-3-amino-1-hydroxy pyrrolidin-2-one and its use as a neuroprotective agent | MERCK & CO., INC. (US) | 1989-09-05 | — | — | US | disclosed |
| US-RE32992-E | THERAPY FOR INFECTIOUS DISEASES CAUSED BY PATHOGENIC MICROORGANISMS | Fujisawa Pharaceutical Co., Ltd. (JP) | 1989-07-18 | — | — | US | disclosed |
| US-4847242-A | ANTIBIOTICS | BEECHAM GROUP P.L.C. (GB) | 1989-07-11 | — | — | US | disclosed |
| EP-0321185-A2 | Erythromycin derivatives | BEECHAM GROUP PLC (GB) | 1989-06-21 | — | — | EP | disclosed |
| EP-0318091-A2 | Resolved amino pyrrolidine neuroprotective agents | MERCK SHARP & DOHME LTD. (GB) | 1989-05-31 | — | — | EP | disclosed |
| EP-0098456-B1 | PEPTIDES COMPRISING A (1S,2R,3R)- OR (1R,2S,3S)-1-NITRILO-1-CARBONYL-3-METHYL-2-OXY-HEPTANE OR -HEPT-5-ENE RESIDUE USEFUL IN THE TOTAL SYNTHESIS OF CYCLOSPORINS, AND PROCESSES FOR THEIR PRODUCTION | SANDOZ AG (CH) | 1989-05-24 | — | — | EP | disclosed |
| US-4826820-A | BACTERICIDES | BEECHAM GROUP P.L.C. (GB) | 1989-05-02 | — | — | US | disclosed |
| EP-0307177-A2 | Erythromycin derivatives | BEECHAM GROUP PLC (GB) | 1989-03-15 | — | — | EP | disclosed |
| US-4810817-A | ARTIFICIAL SWEETENERS | W. R. GRACE & CO. (US) | 1989-03-07 | — | — | US | disclosed |
| US-4806473-A | USING CARBOXYPEPTIDASE Y TO CLEAVE PROTECTIVE GROUPS; PRODUCING DI-, TRI- AND TETRAPEPTIDES | De Forenede Bryggeier A/S (DK) | 1989-02-21 | — | — | US | disclosed |
| EP-0302442-A2 | Vibriolysin coupling process | W.R. Grace & Co.-Conn. (US) | 1989-02-08 | — | — | EP | disclosed |
| US-4801580-A | Peptide, process for preparation thereof and use thereof | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1989-01-31 | — | — | US | disclosed |
| US-4795809-A | CLAVULANIC ACID INTERMEDIATE | BEECHAM GROUP PLC (GB) | 1989-01-03 | — | — | US | disclosed |
| WO-1988010264-A1 | NUCLEOSIDE DERIVATIVES | HOWARD FLOREY INSTITUTE OF EXPERIMENTAL PHYSIOLOGY (AU) | 1988-12-29 | — | — | WO | disclosed |
| EP-0284203-A2 | Erythromycin derivatives, process for their preparation and their pharmaceutical use | BEECHAM GROUP PLC (GB) | 1988-09-28 | — | — | EP | disclosed |
| US-4767863-A | Isoxazoline intermediates | BRISTOL-MYERS COMPANY (US) | 1988-08-30 | — | — | US | disclosed |
| EP-0279681-A2 | Saturated heterocyclic carboxamide derivatives | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1988-08-24 | — | — | EP | disclosed |
| EP-0272564-A2 | Enzyme mediated coupling reactions | HAMPSHIRE CHEMICAL CORPORATION (US) | 1988-06-29 | — | — | EP | disclosed |
| US-4749691-A | Peptide, process for preparation thereof and use thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1988-06-07 | — | — | US | disclosed |
| US-4743593-A | ANTIBIOTICS | BEECHAM GROUP P.L.C. (GB) | 1988-05-10 | — | — | US | disclosed |
| US-4725582-A | IMMUNE RESPONSE ENHANCERS | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1988-02-16 | — | — | US | disclosed |
| US-4717767-A | ANTIBIOTICS | TOYAMA CHEMICAL CO., LTD. (JP) | 1988-01-05 | — | — | US | disclosed |
| US-4710583-A | ENZYMATIC COUPLING OF PHENYLSERINE WITH ASPARTIC ACID; HYDROGENATION | W. R. GRACE & CO. (US) | 1987-12-01 | — | — | US | disclosed |
| US-4703106-A | REDUCING CALCIUM CONCENTRATION OF BLOOD | MITSUBISHI PETROCHEMICAL CO., LTD. (JP) | 1987-10-27 | — | — | US | disclosed |
| US-4698352-A | 4-oxo-1,4-dihydronicotinic acid derivatives, salts thereof, and antibacterial agents containing the same | TOYAMA CHEMICAL CO., LTD. (JP) | 1987-10-06 | — | — | US | disclosed |
| US-4692538-A | CHEMICAL INTERMEDIATES FOR ANTITUMOR AGENTS | BRISTOL-MYERS COMPANY (US) | 1987-09-08 | — | — | US | disclosed |
| EP-0098457-B1 | (1S,2R,3R)- AND (1R,2S,3S)-NITRILO-1-CARBONYL-3-METHYL-2-OXY-HEPTANES AND -HEPT-5-ENES USEFUL IN THE TOTAL SYNTHESIS OF CYCLOSPORINS AND PROCESSES FOR THEIR PRODUCTION | SANDOZ AG (CH) | 1987-08-05 | — | — | EP | disclosed |
| US-4673738-A | Novel intermediates of cephalosporins and process for producing 7-(substituted or unsubstituted amino)-3-substituted methyl-Δ3 -cephem-4-carboxylic acids | HANDI-PAC INC. (US) | 1987-06-16 | — | — | US | disclosed |
| EP-0025842-B1 | PEPTIDES, PROCESS FOR THEIR PREPARATION, THEIR PHARMACEUTICAL COMPOSITIONS AND THEIR INTERMEDIATES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1987-06-03 | — | — | EP | disclosed |
| EP-0220923-A2 | Dipeptides and process | W.R. Grace & Co.-Conn. (US) | 1987-05-06 | — | — | EP | disclosed |
| EP-0216169-A2 | Erythromycin derivatives | BEECHAM GROUP PLC (GB) | 1987-04-01 | — | — | EP | disclosed |
| EP-0213914-A2 | Clavam derivatives, preparation and intermediates therefor | BEECHAM GROUP PLC (GB) | 1987-03-11 | — | — | EP | disclosed |
| US-4643849-A | ANTIULCER, ANTISECRETORY AGENTS | TOYAMA CHEMICAL CO., LTD. (JP) | 1987-02-17 | — | — | US | disclosed |
| EP-0201166-A1 | Erythromycin derivatives | BEECHAM GROUP PLC (GB) | 1986-11-12 | — | — | EP | disclosed |
| US-4618606-A | Antibiotic 7-(thiazolyl)-3-(pyrazinylmethyl) or (pyridazinylmethyl) cephalosporins | TOYAMA CHEMICAL CO., LTD. (JP) | 1986-10-21 | — | — | US | disclosed |
| US-4614819-A | REACTING A THIOL ESTER COMPOUND WITH 7-AMINOCEPHALOSPORIN IN PRESENCE OF BORON TRIFLUORIDE | TOYAMA CHEMICAL CO., LTD. (JP) | 1986-09-30 | — | — | US | disclosed |
| EP-0194833-A2 | Erythromycin derivatives | BEECHAM GROUP PLC (GB) | 1986-09-17 | — | — | EP | disclosed |
| US-4610983-A | N-acyl acidic amino acid diamide derivative, a salt thereof, and an anti-ulcer agent containing the same | TOYAMA CHEMICAL CO., LTD. (JP) | 1986-09-09 | — | — | US | disclosed |
| EP-0190278-A1 | ERYTHROMYCIN DERIVATIVES | BEECHAM GROUP PLC (GB) | 1986-08-13 | — | — | EP | disclosed |
| EP-0184921-A2 | Erythromycin derivatives | BEECHAM GROUP PLC (GB) | 1986-06-18 | — | — | EP | disclosed |
| EP-0181121-A2 | Novel polypeptide and process for producing the same | MITSUBISHI PETROCHEMICAL CO., LTD. (JP) | 1986-05-14 | — | — | EP | disclosed |
| WO-1986001513-A1 | ERYTHROMYCIN DERIVATIVES | BEECHAM GROUP, P.L.C. (GB) | 1986-03-13 | — | — | WO | disclosed |
| US-4563534-A | Process for producing 2-(2-aminothiazol-4-yl)glyoxylic acid derivative or a salt thereof, and intermediates therefor and process for producing the intermediates | TOYAMA CHEMICAL CO., LTD. (JP) | 1986-01-07 | — | — | US | disclosed |
| US-4554351-A | STEREOISOMERS | SANDOZ LTD. (CH) | 1985-11-19 | — | — | US | disclosed |
| US-4539155-A | New peptide, process for preparation thereof and use thereof | FUISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1985-09-03 | — | — | US | disclosed |
| EP-0057412-B1 | PEPTIDE, PROCESS FOR PREPARATION THEREOF AND USE THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1985-05-22 | — | — | EP | disclosed |
| US-4518773-A | \"3-Carbamoyloxy cephalosporins\ | BRISTOL-MYERS COMPANY (US) | 1985-05-21 | — | — | US | disclosed |
| US-4512980-A | IMMUNOLOGICALLY EFFECTIVE | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 1985-04-23 | — | — | US | disclosed |
| EP-0027260-B1 | PEPTIDES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1985-03-13 | — | — | EP | disclosed |
| US-4504584-A | PEPTIDE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1985-03-12 | — | — | US | disclosed |
| US-4489072-A | BACTERICIDE, ANTIBIOTIC | TOYAMA CHEMICAL CO., LTD. (JP) | 1984-12-18 | — | — | US | disclosed |
| US-4487763-A | BACTERICIDE, FUNGICIDE, ANTIBODY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-12-11 | — | — | US | disclosed |
| EP-0017485-B1 | A PROCESS FOR ENZYMATIC PRODUCTION OF PEPTIDES | DE FORENEDE BRYGGERIER A/S (DK) | 1984-09-26 | — | — | EP | disclosed |
| EP-0114787-A2 | Peptide derivatives | CIBA-GEIGY AG (CH) | 1984-08-01 | — | — | EP | disclosed |
| US-4458078-A | SYNTHESIS OF OLIGOPEPTIDES | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1984-07-03 | — | — | US | disclosed |
| US-4447436-A | 1,2,3,4-Tetrahydroisoquinolines 6.10,7,8 dihydroxy substitute-1-methylanilino and use as smooth muscle relaxants | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-05-08 | — | — | US | disclosed |
| US-4439425-A | IMMUNOLOGY | CIBA-GEIGY CORPORATION (US) | 1984-03-27 | — | — | US | disclosed |
| US-4435321-A | BACTERICIDES AND INTERMEDIATES FOR 2- OR 3-CEPHEMS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-03-06 | — | — | US | disclosed |
| US-4427581-A | BACTERICIDES, FUNGICIDES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-01-24 | — | — | US | disclosed |
| EP-0098457-A2 | (1S,2R,3R)- and (1R,2S,3S)-nitrilo-1-carbonyl-3-methyl-2-oxy-heptanes and -hept-5-enes useful in the total synthesis of cyclosporins and processes for their production | SANDOZ AG (CH) | 1984-01-18 | — | — | EP | disclosed |
| EP-0098456-A2 | Peptides comprising a (1S,2R,3R)- or (1R,2S,3S)-1-nitrilo-1-carbonyl-3-methyl-2-oxy-heptane or -hept-5-ene residue useful in the total synthesis of cyclosporins, and processes for their production | SANDOZ AG (CH) | 1984-01-18 | — | — | EP | disclosed |
| US-4426520-A | CEPHALOSPORIN ANTIBIOTICS | BRISTOL-MYERS COMPANY (US) | 1984-01-17 | — | — | US | disclosed |
| US-4410458-A | GROUP 5B OR 6B METAL COMPOUND OXIDATION CATALYST | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-10-18 | — | — | US | disclosed |
| US-4407755-A | BACTERICIDAL PENICILLINS | BRISTOL-MYERS COMPANY (US) | 1983-10-04 | — | — | US | disclosed |
| US-4400316-A | POLYPEPTIDES | TOYO JOZO KABUSHIKI KAISHA (JP) | 1983-08-23 | — | — | US | disclosed |
| US-4396542-A | Method for the total synthesis of cyclosporins, novel cyclosporins and novel intermediates and methods for their production | SANDOZ LTD. (CH) | 1983-08-02 | — | — | US | disclosed |
| US-4395412-A | 7α-Methoxycephalosporins | TOYAMA CHEMICAL CO., LTD. (JP) | 1983-07-26 | — | — | US | disclosed |
| US-4385178-A | REACTION OF A CEPHALOSPORANIC ACID WITH A THIOL COMPOUND IN THE PRESENCE OF BORON TRIFLUORIDE | TOYAMA CHEMICAL CO., LTD. (JP) | 1983-05-24 | — | — | US | disclosed |
| US-4374982-A | Cepham compounds | BRISTOL-MYERS COMPANY (US) | 1983-02-22 | — | — | US | disclosed |
| US-4370332-A | MUSCLE RELAXANTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-01-25 | — | — | US | disclosed |
| US-4354966-A | Peptides, process for preparation thereof and use thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1982-10-19 | — | — | US | disclosed |
| EP-0057412-A1 | Peptide, process for preparation thereof and use thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1982-08-11 | — | — | EP | disclosed |
| EP-0011283-B1 | NEW LACTYL TETRAPEPTIDE, PROCESSES FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1982-07-28 | — | — | EP | disclosed |
| US-4339534-A | USING A CARBOXYPEPTIDASE ENZYME; ENZYMES/HYDROLASES/; PROTEOLYTIC ENZYMES; DEESTERIFICATION, AMIDATION; CLEAVAGE/C-N/; | DE FORENEDE BRYGGERIER A/S (DK) | 1982-07-13 | — | — | US | disclosed |
| US-4334014-A | CONTAINING A CEPHALOSPORIN | FUJI PHOTO FILM CO., LTD. (JP) | 1982-06-08 | — | — | US | disclosed |
| US-4322347-A | 2-Carbamoyloxymethyl-penicillin derivatives | BRISTOL-MYERS COMPANY (US) | 1982-03-30 | — | — | US | disclosed |
| US-4321265-A | 7α-Methoxycephalosporins | TOYAMA CHEMICAL CO., LTD. (JP) | 1982-03-23 | — | — | US | disclosed |
| US-4317907-A | ANHYDROUS CONDITIONS IN THE PRESENCE OF BOREN TRIFLUORIDE OR ONE OF ITS COMPLEXES | TOYAMA CHEMICAL CO., LTD. (JP) | 1982-03-02 | — | — | US | disclosed |
| EP-0000252-B1 | PEPTIDES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE PEPTIDES AND A PROCESS FOR THE PREPARATION OF THE PEPTIDES | BEECHAM GROUP PLC (GB) | 1982-02-03 | — | — | EP | disclosed |
| US-4312986-A | REACTION OF CORRESPONDING ESTER OR CARBAMATE WITH MERCAPTO COMPOUND | TOYAMA CHEMICAL CO., LTD. (JP) | 1982-01-26 | — | — | US | disclosed |
| US-4311640-A | ANTIBIOTIC | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1982-01-19 | — | — | US | disclosed |
| US-4310459-A | Process for producing carbamoyl substituted penams and carbamoyl substituted cephams from penicillin sulfoxide esters | BRISTOL-MYERS COMPANY (US) | 1982-01-12 | — | — | US | disclosed |
| US-4293648-A | Process for esterification of α-L-aspartyl-L-phenylalanine | G. D. SEARLE & CO. (US) | 1981-10-06 | — | — | US | disclosed |
| US-4292320-A | SMOOTH MUSCLE RELAXANTS | FUJISAWA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1981-09-29 | — | — | US | disclosed |
| EP-0034567-A2 | A method for the total synthesis of cyclosporins and novel cyclosporins | SANDOZ AG (CH) | 1981-08-26 | — | — | EP | disclosed |
| EP-0000330-B1 | LIPOPEPTIDES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CIBA-GEIGY AG (CH) | 1981-08-05 | — | — | EP | disclosed |
| US-4273704-A | N-Adamantane-substituted tetrapeptide amides | G. D. SEARLE & CO. (US) | 1981-06-16 | — | — | US | disclosed |
| US-4271068-A | Process for the manufacture of cystine-containing peptides | CIBA-GEIGY CORPORATION (US) | 1981-06-02 | — | — | US | disclosed |
| US-4267340-A | BACTERICIDES; SYNTHESIS OF PENICILLINS AND CEPHALOSPORINS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-05-12 | — | — | US | disclosed |
| US-4265892-A | Cephalosporins having an α-acylaminoacetic acid side chain | CIBA-GEIGY CORPORATION (US) | 1981-05-05 | — | — | US | disclosed |
| EP-0027260-A2 | Peptides, processes for their preparation and pharmaceutical compositions containing them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-04-22 | — | — | EP | disclosed |
| US-4263292-A | BROAD SPECTRUM ANTIBIOTICS | TOYAMA CHEMICAL CO., LTD. (JP) | 1981-04-21 | — | — | US | disclosed |
| EP-0025842-A2 | Peptides, process for their preparation, their pharmaceutical compositions and their intermediates | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-04-01 | — | — | EP | disclosed |
| US-4258193-A | FOR IMMOBILIZATION; IMMUNOASSAY, CROSSLINKING OF PROTEINS | TOYO JOZO KABUSHIKI KAISHA (JP) | 1981-03-24 | — | — | US | disclosed |
| US-4246405-A | Method for preparation of β-lactam compound | FUJISAWA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1981-01-20 | — | — | US | disclosed |
| WO-1980002157-A1 | A PROCESS FOR ENZYMATIC PRODUCTION OF PEPTIDES | FORENEDE BRYGGERIER AS (DK) | 1980-10-16 | — | — | WO | disclosed |
| EP-0017485-A1 | A process for enzymatic production of peptides | DE FORENEDE BRYGGERIER A/S (DK) | 1980-10-15 | — | — | EP | disclosed |
| US-4223016-A | ALLERGY DESENSITIZATION | BEECHAM GROUP LIMITED (GB) | 1980-09-16 | — | — | US | disclosed |
| EP-0014815-A2 | Peptide derivatives, process for their preparation and intermediates, and pharmaceutical compositions containing one of these compounds | CIBA-GEIGY AG (CH) | 1980-09-03 | — | — | EP | disclosed |
| US-4220647-A | MUSCLE RELAXANTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-09-02 | — | — | US | disclosed |
| EP-0011283-A1 | New lactyl tetrapeptide, processes for preparation thereof and pharmaceutical compositions containing it | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-05-28 | — | — | EP | disclosed |
| US-4202900-A | Derivatives of penam-3-carboxylic acid and a pharmaceutical composition containing the same | CIBA-GEIGY CORPORATION (US) | 1980-05-13 | — | — | US | disclosed |
| US-4187374-A | 7-(β-Aminoacylamino)-3-substituted-3-cephem-4-carboxylic acid derivatives and preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-02-05 | — | — | US | disclosed |
| US-4176009-A | HYDROLYZING OLIGOPEPTIDES IN A AQUEOUS SOLUTION TO RELEASE PEPTIDE FRAGMENTS, USING COLORIMETRIC ANALYSIS AFTER SOLVENT EXTRACTION | AJINOMOTO CO., INC. (JP) | 1979-11-27 | — | — | US | disclosed |
| US-4159981-A | CYCLIC POLYPEPTIDES, DEETHERIFICATION, DEESTERIFICATION | CIBA-GEIGY CORPORATION (US) | 1979-07-03 | — | — | US | disclosed |
| US-4154831-A | Cephalosporins having an α-acylaminoacetic acid side chain | CIBA-GEIGY CORPORATION (US) | 1979-05-15 | — | — | US | disclosed |
| US-4144228-A | Methionine5 -enkephalin sulfoxides and sulfones | G. D. SEARLE & CO. (US) | 1979-03-13 | — | — | US | disclosed |
| US-4138394-A | Peptide derivatives and a method of measuring collagenase activity | AJINOMOTO CO., INC. (JP) | 1979-02-06 | — | — | US | disclosed |
| EP-0000330-A1 | Lipopeptides, process for their preparation and pharmaceutical compositions containing them | CIBA-GEIGY AG (CH) | 1979-01-24 | — | — | EP | disclosed |
| EP-0000252-A1 | Peptides, pharmaceutical compositions containing the peptides and a process for the preparation of the peptides | BEECHAM GROUP PLC (GB) | 1979-01-10 | — | — | EP | disclosed |
| US-4119493-A | IN PRESENCE OF METALLOPROTEINASE ENZYME | (ZAIDANHOJIN) SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1978-10-10 | — | — | US | disclosed |
| US-4116768-A | AMIDATION, METALLOPROTEINASE ENZYME | (ZAIDANHOJIN) SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1978-09-26 | — | — | US | disclosed |
| US-4115566-A | 7α Ureido cephem-4-carboxylic acid derivatives | CIBA-GEIGY CORPORATION (US) | 1978-09-19 | — | — | US | disclosed |
| US-4094872-A | 7-(β-Aminoacylamino)-3-heterocyclic-thiomethyl-3-cephem-4-carboxylic acid derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JA) | 1978-06-13 | — | — | US | disclosed |
| US-4092304-A | OLIGOPEPTIDE; ANALGESICS, ANTIDIARRHEAL AGENTS, NON-ADDICTING NARCOTIC ANTAGONISTS | G. D. SEARLE & CO. (US) | 1978-05-30 | — | — | US | disclosed |
| US-4086221-A | SERUM CALCIUM REDUCING ACTIVITY | TOYO JOZO KABUSHIKI KAISHA (JA) | 1978-04-25 | — | — | US | disclosed |
| US-4086136-A | Process for producing a peptide using a serine or thiol proteinase | (ZAIDANHOJIN) SAGAMI CHEMICAL RESEARCH CENTER (JA) | 1978-04-25 | — | — | US | disclosed |
| US-4071527-A | Certain benzothiazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JA) | 1978-01-31 | — | — | US | disclosed |
| US-4041161-A | ANTIBIOTICS | CIBA-GEIGY CORPORATION (US) | 1977-08-09 | — | — | US | disclosed |
| US-4036847-A | ANTIBACTERIAL | FUJISAWA PHARMACEUTICAL CO., LTD. (JA) | 1977-07-19 | — | — | US | disclosed |
| US-4028319-A | 2 AND 3-SUBSTITUTED ENKEPHALINS | G. D. SEARLE & CO. (US) | 1977-06-07 | — | — | US | disclosed |
| US-4015000-A | 6-Acylamino-penam-3-carboxylic and 7-acylamino-3-cephem-4-carboxylic acids | CIBA-GEIGY CORPORATION (US) | 1977-03-29 | — | — | US | disclosed |
| US-4012367-A | Anti-ulcer polypeptides containing L-aspartic acid and intermediates thereto | G. D. SEARLE & CO. (US) | 1977-03-15 | — | — | US | disclosed |
| US-4009159-A | PENICILLINS | FUJISAWA PHARMACEUTICAL CO., LTD. (JA) | 1977-02-22 | — | — | US | disclosed |
| US-3994871-A | Process for the manufacture of peptides containing cystine | CIBA-GEIGY CORPORATION (US) | 1976-11-30 | — | — | US | disclosed |
| US-3993646-A | Process for the ring expansion of penicillins to cephalosporin compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JA) | 1976-11-23 | — | — | US | disclosed |
| US-3978063-A | 1,2,3,4-Tetrahydroisoquinoline derivatives and the preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JA) | 1976-08-31 | — | — | US | disclosed |
| US-3963725-A | 1,2,3,4-Tetrahydroisoquinoline derivatives and the preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JA) | 1976-06-15 | — | — | US | disclosed |
| US-3956260-A | ANTIINFLAMMATORY | CIBA-GEIGY CORPORATION (US) | 1976-05-11 | — | — | US | disclosed |
| US-3954802-A | Substituted-ureido derivatives of penam 3-carboxylic acid and cephem 4-carboxylic acid | CIBA-GEIGY CORPORATION (US) | 1976-05-04 | — | — | US | disclosed |
| US-3934008-A | PEPTIDES, HYPOCALCAEMIC | CIBA-GEIGY CORPORATION (US) | 1976-01-20 | — | — | US | disclosed |
| US-3934008-A | PEPTIDES, HYPOCALCAEMIC | CIBA-GEIGY CORPORATION (US) | 1976-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184750-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | MEN1 3502/4885KMT2A 3558/4885NPC1 4421/4885 |
| US-10961273-B2 | N-carboxyanhydride-based-scale synthesis of elamipretide | MTPN, TUFM, PDF | MEN1 1181/4885KMT2A 4447/4885NPC1 3458/4885 |
| US-10450316-B2 | Certain protein kinase inhibitor | CDK4, CDK6, CDK2 | MEN1 1816/4885KMT2A 845/4885NPC1 3289/4885 |
| US-20210024528-A1 | SUBSTITUTED (2-AZABICYCLO[3.1.0]HEXAN-2-YL)PYRAZOLO[1,5-a]PYRIMIDINE AND IMIDAZO[1,2-b]PYRIDAZINE COMPOUNDS AS TRK KINASES INHIBITORS | PLK2, DMPK, MAP4K2 | MEN1 3533/4885KMT2A 1284/4885NPC1 4086/4885 |
| US-20110306615-A1 | NOVEL IMIDAZOLIDINE DERIVATIVE AND USE THEREOF | CBR1, NR0B1, CNKSR1 | MEN1 1708/4885KMT2A 2716/4885NPC1 2435/4885 |
| US-20200345717-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BAX, BCL2, BCL3 | MEN1 3662/4885KMT2A 3919/4885NPC1 4449/4885 |
| US-20210008219-A1 | LONG-ACTING ADRENOMEDULLIN DERIVATIVE | CRH, NPPA, AVPR1B | MEN1 132/4885KMT2A 1985/4885NPC1 2362/4885 |
| US-20190345156-A1 | COMPOUNDS AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS | BCL2, BAX, BCL2L1 | MEN1 2951/4885KMT2A 3450/4885NPC1 2522/4885 |
| US-20090149478-A1 | NOVEL COMBINATION ANTICANCER AGENTS | KRAS, TOP1, ERBB3 | MEN1 782/4885KMT2A 1852/4885NPC1 1898/4885 |
| US-20230159527-A1 | COMPOUNDS AS BCL-2 INHIBITORS | BCL2, BCL2L2, BCL2L1 | MEN1 4012/4885KMT2A 2209/4885NPC1 1649/4885 |
| US-20050037370-A1 | Oligomeric compounds having modified bases for binding to adenine and guanine and their use in gene modulation | RNMT, RRBP1, G3BP1 | MEN1 3504/4885KMT2A 3013/4885NPC1 2945/4885 |
| US-20060128706-A1 | Apoptosis promoters | BAX, BCL2, API5 | MEN1 4483/4885KMT2A 4140/4885NPC1 2977/4885 |
| US-11730826-B2 | Amphiphilic nanoparticles for delivery of CRISPR based therapy | ABCB4, ABCB1, ZFR | MEN1 2357/4885KMT2A 567/4885NPC1 69/4885 |
| US-20210253634-A1 | PROCESS FOR THE LIQUID PHASE SYNTHESIS OF H-INP-(D)BAL-(D)TRP-PHE-APC-NH2, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | VIP, IAPP, PROKR1 | MEN1 182/4885KMT2A 3727/4885NPC1 1148/4885 |
| US-20200172572-A1 | PROCESS FOR THE LIQUID PHASE SYNTHESIS OF H-INP-(D)BAL-(D)TRP-PHE-APC-NH2, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | VIP, IAPP, PROKR1 | MEN1 182/4885KMT2A 3727/4885NPC1 1148/4885 |
| US-20230145305-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, ABL1, LCK | MEN1 2898/4885KMT2A 1204/4885NPC1 3164/4885 |
| US-20180251426-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | MEN1 3502/4885KMT2A 3558/4885NPC1 4421/4885 |
| US-20110144112-A9 | APOPTOSIS PROMOTERS | BAX, BCL2, API5 | MEN1 4483/4885KMT2A 4140/4885NPC1 2977/4885 |
| US-20140113910-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | MEN1 3502/4885KMT2A 3558/4885NPC1 4421/4885 |
| US-20120028925-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | MEN1 3502/4885KMT2A 3558/4885NPC1 4421/4885 |
| US-20130296295-A1 | BCL-2 SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | BCL2, BCL3, BCL2L1 | MEN1 4415/4885KMT2A 3218/4885NPC1 3616/4885 |
| US-20130096120-A1 | APOPTOSIS-INDUCED AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BAX, BCL2, BCL3 | MEN1 3779/4885KMT2A 3907/4885NPC1 4425/4885 |
| US-20220041588-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ABL1, ERBB2 | MEN1 1360/4885KMT2A 567/4885NPC1 3649/4885 |
| US-20030008814-A1 | Pseudomycin phosphate prodrugs | PMM2, ME1, BPGM | MEN1 634/4885KMT2A 1484/4885NPC1 1736/4885 |
| US-20150072978-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BAX, BCL2, BCL3 | MEN1 3662/4885KMT2A 3919/4885NPC1 4449/4885 |
| US-20170218015-A1 | PROCESS FOR THE LIQUID PHASE SYNTHESIS OF H-INP-(D)BAL-(D)TRP-PHE-APC-NH2, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | VIP, IAPP, PROKR1 | MEN1 182/4885KMT2A 3727/4885NPC1 1148/4885 |
| US-20010003741-A1 | Aminoalcohol derivative and medicament comprising the same | SGMS2, FABP7, SGMS1 | MEN1 2933/4885KMT2A 2489/4885NPC1 77/4885 |
| US-20100298323-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | MEN1 3502/4885KMT2A 3558/4885NPC1 4421/4885 |
| US-20110160468-A1 | PROCESS FOR THE PREPARATION OF (3R,3AS,6AR)-HEXAHYDROFURO [2,3-B] FURAN-3-YL (1S,2R)-3-[[(4-AMINOPHENYL) SULFONYL] (ISOBUTYL) AMINO]-1-BENZYL-2-HYDROXYPROPYLCARBAMATE | HTR3C, HPD, HAAO | MEN1 4859/4885KMT2A 2401/4885NPC1 2217/4885 |
| US-20100152183-A1 | BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | BCL2, BCL3, BCL2L1 | MEN1 4406/4885KMT2A 3120/4885NPC1 3579/4885 |
| US-20030130213-A1 | Novel pyrazine derivatives or salts thereof, pharmaceutical composition containing the same, and production intermediates thereof | GTF3C5, EIF2AK2, GTF3C2 | MEN1 3809/4885KMT2A 1665/4885NPC1 2651/4885 |
| US-20100305122-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | MEN1 3634/4885KMT2A 3560/4885NPC1 4443/4885 |
| US-20220402913-A1 | APOPTOSIS-INDUCING AGENTS | BCL2, BAX, BAD | MEN1 4545/4885KMT2A 3915/4885NPC1 2599/4885 |
| US-20230405080-A1 | METHODS AND COMPOSITIONS FOR TREATING, PREVENTING, INHIBITING, AMELIORATING OR DELAYING THE ONSET OF OPHTHALMIC CONDITIONS | UACA, EYA3, ALDH1A2 | MEN1 3020/4885KMT2A 4770/4885NPC1 477/4885 |
| US-20180264123-A1 | LONG-ACTING ADRENOMEDULLIN DERIVATIVE | CRH, NPPA, VIP | MEN1 127/4885KMT2A 2050/4885NPC1 2448/4885 |
| US-20130190488-A1 | APOPTOSIS PROMOTERS | BAX, BCL2, API5 | MEN1 4483/4885KMT2A 4140/4885NPC1 2977/4885 |
| US-20210106679-A1 | Silaffin Silica Particle Adjuvant | MICA, SF3A1, SFXN1 | MEN1 909/4885KMT2A 1194/4885NPC1 3694/4885 |
| US-20070123574-A1 | Methods for the preparation of benzoxazole sulfonamide compounds and intermediates thereof | STS, MPST, SULT1E1 | MEN1 4591/4885KMT2A 921/4885NPC1 1896/4885 |
| US-11053239-B2 | Compounds as BLC-2-selective apoptosis-inducing agents | BCL2, BAX, BAD | MEN1 3979/4885KMT2A 2560/4885NPC1 2054/4885 |
| US-20070015787-A1 | Apoptosis promoters | BAX, BCL2, API5 | MEN1 4483/4885KMT2A 4140/4885NPC1 2977/4885 |
| US-20200222413-A1 | METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L10 | MEN1 3322/4885KMT2A 2472/4885NPC1 3903/4885 |
| US-20060205709-A1 | Preventive/remedy for retinal nerve diseases containing alkyl ether derivatives or salts thereof | RB1, ALDH1A2, NR2E3 | MEN1 2799/4885KMT2A 4027/4885NPC1 370/4885 |
| US-20050113424-A1 | Novel arylamidine derivative or salt thereof | SLC7A1, NAT1, NACA | MEN1 2216/4885KMT2A 2407/4885NPC1 618/4885 |
| US-20080027211-A1 | Enantiopure Heterocyclic Compound Useful for the Preparation of Peptides Which Can Be Potentially Used as Medicaments | NPR3, VIP, NPPA | MEN1 206/4885KMT2A 4324/4885NPC1 1112/4885 |
| US-20050250843-A1 | Medicinal compositions improving brain function and method for improving brain function | CHRM2, ACHE, CHAT | MEN1 3544/4885KMT2A 1276/4885NPC1 240/4885 |
| US-20100184766-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | MEN1 3502/4885KMT2A 3558/4885NPC1 4421/4885 |
| US-20150329541-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | MEN1 3634/4885KMT2A 3560/4885NPC1 4443/4885 |
| US-10751423-B2 | Nanoparticle conjugates of highly potent toxins and intraperitoneal administration of nanoparticles for treating or imaging cancer | ANXA4, ANXA3, CD47 | MEN1 1957/4885KMT2A 4582/4885NPC1 3274/4885 |
| US-20170362609-A1 | AMPHIPHILIC NANOPARTICLES FOR CODELIVERY OF WATER-INSOLUBLE SMALL MOLECULES AND RNAi | ZFR, TP53, ABCD3 | MEN1 3262/4885KMT2A 377/4885NPC1 211/4885 |
| US-20110112066-A1 | PREVENTIVE/REMEDY FOR RETINAL NERVE DISEASES CONTAINING ALKYL ETHER DERIVATIVES OR SALTS THEREOF | RB1, ALDH1A2, NR2E3 | MEN1 2799/4885KMT2A 4027/4885NPC1 370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.